Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5888736 A
Publication typeGrant
Application numberUS 08/807,138
Publication dateMar 30, 1999
Filing dateFeb 27, 1997
Priority dateDec 22, 1995
Fee statusPaid
Also published asWO1997041257A1
Publication number08807138, 807138, US 5888736 A, US 5888736A, US-A-5888736, US5888736 A, US5888736A
InventorsJean-Michel Lacroix, James Leushner, May Hui, James M. Dunn, Marina T. Larson
Original AssigneeVisible Genetics, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Method, compositions and kit for detection and identification of microorganisms
US 5888736 A
Abstract
Evaluation of a sample for the presence and qualitative nature of a microorganism can be performed in a single vessel by combining a natural abundance DNA sample with a sequencing mixture containing a primer pair, a thermally stable polymerase such as ThermoSequenase™ which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than about 0.4 times the rate of incorporation of deoxynucleotides, nucleotide triphosphate feedstocks, and a chain terminating nucleotide triphosphate. The mixture is processed through multiple thermal cycles for annealing, extension and denaturation to produce a product mixture which is analyzed by electrophoresis.
Images(72)
Previous page
Next page
Claims(11)
We claim:
1. A method for evaluating a natural abundance sample for the presence of a target DNA sequence from a target microorganism, said natural abundance sample containing the target DNA sequence substantially without preferential amplification of the target DNA sequence relative to non-target DNA sequences in the sample, comprising the steps of:
(a) combining the natural abundance sample directly and in a single reaction mixture with first and second primers, a nucleotide triphosphate feedstock mixture, a chain-terminating nucleotide triphosphate and a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides in an amplification mixture, said first and second primers binding to the sense and antisense strands, respectively, and flanking the target DNA sequence within the target microorganism genome, and at least one of said first and second primers being labeled with a fluorescent label;
(b) exposing the reaction mixture to a plurality of temperature cycles each of which includes at least a high temperature denaturation phase and a lower temperature extension phase, thereby producing a plurality of species of terminated fragments if DNA from the target microorganism is present in the natural abundance sample, each species of terminated fragment corresponding to a different incorporation position for the chain-terminating nucleotide triphosphate in the DNA of the target microorganism DNA;
(c) evaluating the terminated fragments produced to determine the incorporation positions of the chain-terminating nucleotide triphosphate; and
(d) comparing the incorporation positions of the chain-terminating nucleotide triphosphate to the target DNA sequence to determine if the target DNA sequence is present in the sample.
2. The method of claim 1, wherein the first and second primers are each labeled with a different fluorescent label.
3. The method of claim 1, wherein the chain terminating nucleotide triphosphate is present in a mole ratio to the corresponding nucleotide triphosphate of from 1:50 to 1:1000.
4. The method of claim 3, wherein the mole ratio of the chain terminating nucleotide triphosphate to the corresponding nucleotide triphosphate is from 1:100 to 1:500.
5. The method according to claim 1, wherein the target microorganism is Chlamydia trachomatis.
6. The method according to claim 5, wherein the first and second primers are selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 1-17.
7. The method according to claim 1, wherein the target microorganism is human immunodeficiency virus.
8. The method according to claim 7, wherein the first and second primers are selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos. 18-20.
9. The method according to claim 1, wherein the target microorganism is human papilloma virus.
10. The method according to claim 9, wherein the first and second primers are selected from among the group consisting of the oligonucleotides given by Seq. ID. Nos.21-22.
11. A method for evaluating a natural abundance sample for the presence of a target DNA sequence from a target microorganism, said natural abundance sample containing the target DNA sequence substantially without preferential amplification of the target DNA sequence relative to non-target DNA sequences in the sample, comprising the steps of:
(a) combining each of from one to three aliquots of the natural abundance sample directly and in a single reaction mixture with first and second primers, a nucleotide triphosphate feedstock mixture, a single chain-terminating nucleotide triphosphate and a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides in an amplification mixture to form a reaction mixture, said first and second primers binding to the sense and antisense strands, respectively, and flanking the target DNA sequence within the target microorganism genome, and at least one of said first and second primers being labeled with a fluorescent label, wherein the chain-terminating nucleotide triphosphate added to each aliquot is different from that added to the other aliquots;
(b) exposing the reaction mixture to a plurality of temperature cycles each of which includes at least a high temperature denaturation phase and a lower temperature extension phase, thereby producing a plurality of species of terminated fragments if DNA from the target microorganism is present in the natural abundance sample, each species of terminated fragment corresponding to a different incorporation position for the chain-terminating nucleotide triphosphate in the DNA of the target microorganism DNA;
(c) evaluating the terminated fragments produced to determine the incorporation positions of the chain-terminating nucleotide triphosphate; and
(d) comparing the incorporation positions of the chain-terminating nucleotide triphosphate to the target DNA sequence to determine if the target DNA sequence is present in the sample.
Description

This application is a continuation-in-part of U.S. patent applications Ser. Nos. 08/684,498, filed Jul. 19, 1996, now U.S. Pat. No. 5,830,657; 08/640,672 filed May 1, 1996, now U.S. Pat. No. 5,789,168; and 08/577,858, filed Dec. 22, 1995, now U.S. Pat. No. 5,834,189; which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

This application relates to a method for detection and identification of microorganisms, including in particular pathogenic microorganisms, and to compositions and kits useful in practicing the method. The invention can be applied to detection of viruses, including HIV and hepatitis, bacteria, including Chlamydia, fungi, including Cryptococcus neoformans and protozoa, including Trypanosoma cruzi.

Detection of the presence of pathogenic microorganisms through DNA-based technology is emerging as an important tool in the diagnosis of many diseases. For example, diagnosis of Chlamydia trachomatis infections, the most common bacterial sexually transmitted disease in North America, is shifting from traditional methods such as culture, enzyme immunoassay (EIA) and direct fluorescent antibodies (DFA) to DNA-hybridization diagnostics. Roche Diagnostic Systems, Inc. (Nutley, N.J.) manufactures Amplicor™, a test which detects C. trachomatis and Neisseria gonorrohoeae by the hybridization of a pathogen specific probe to PCR amplified products, detectable by a color change/optical density technique. Abbott Laboratories (Abbott Park, Ill.) makes UriProbe, also a test for C. trachomatis and N. gonorrohoeae, which relies on the ligase chain reaction (LCR). The LCR method, described in Patent Applications WO 9320227, WO 9300447, WO 9408047, WO 9403636, EP 477 972 uses thermostable ligase enzyme to ligate two DNA probes which hybridize in ligatable juxtaposition on a template DNA strand, thus generating a detectable ligated DNA fragment only if the template DNA is present. A multiplex PCR assay for C. trachomatis has also been described in Mahony et al., J. Clin. Microbiol. 33: 3049-3053 (1995).

A wide variety if infectious pathogens that can be detected by DNA-based methods are listed in Diagnostic Molecular Microbiology, Persing et al., eds. American Society for Microbiology, Washington D.C. (1993). This text details diagnostic tests for bacteria, virus, fungi, and protozoa. Diagnostic tests are also proposed for identifying the presence of drug resistance genes or toxin genes.

Although these tests are generally effective for identifying an infectious disease-causing organism if present, they do not routinely provide information concerning the specific serotype, variant or form of the infecting organism. Depending on the organism in question, this information can be significant in determining the likely course of the infection, for determining the most appropriate therapeutic approach and for epidemiological purposes. Furthermore, the previously known assays involve several steps and are therefore more susceptible to systematic error than would be a test with fewer steps. Thus, there remains a need for a simple test format which is generally applicable to the detection of microorganisms, including infectious disease-causing microorganisms, and particularly for a simple test which provides an indication of the specific nature, e.g., the serotype, of the organism. It is an object of the present invention to provide such a test.

It is a further object of the present invention to provide reagent combinations useful in performing tests for infectious disease-causing microorganisms, including Chlamydia human papilloma virus(HPV) and HIV.

It is still a further object of the present invention to provide kits useful in performing tests for infectious disease-causing microorganisms, including Chlamydia, HPV and HIV.

SUMMARY OF THE INVENTION

The present invention provides a method for the evaluation of a sample for the presence of a target microorganism which can be performed directly on a natural abundance DNA preparation obtained from the sample in a single reaction vessel. The method of the invention comprises the steps of:

(a) combining the natural abundance DNA preparation with first and second primers, a nucleotide triphosphate feedstock mixture, a chain-terminating nucleotide triphosphate and a thermally stable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture, said first and second primers binding to the sense and antisense strands of the DNA of the target microorganism, respectively, and flanking a selected region within the genome of the target microorganism;

(b) exposing the reaction mixture to a plurality of temperature cycles each of which includes at least a high temperature denaturation phase and a lower temperature extension phase, thereby producing a plurality of species of terminated fragments if DNA from the target microorganism is present in the sample, each species of terminated fragment corresponding to a different incorporation position for the chain-terminating nucleotide triphosphate in the DNA of the target microorganism; and

(c) evaluating the terminated fragments produced to determine the incorporation positions of the chain-terminating nucleotide triphosphate. Based on the incorporation positions, not only the presence but also the specific nature, e.g. the serotype, of any target microorganism present can be determined.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a novel approach to the evaluation of a sample for the presence of a target microorganism and for the identification of the specific nature of any organism found to be present. The target microorganism may be virus, bacteria, fungi or protozoa. Specific non-limiting examples of microorganisms to which the invention can be suitably applied include bacteria such as Mycobacteria tuberculosis, Rickettsia rickettsii, Ehrlichia chaffeensis, Borrelia burgdorferi, Yersinia pestis, Treponema pallidum, Chlamydia trachomatis, Chlamydia pneumoniae, Mycoplasma pneumoniae, Mycoplasma sp., Legionella pneumophila, Legionella dumoffii, Mycoplasma fermentans, Ehrlichia sp., Haemophilus influenzae, Neisseria meningitidis, Streptococcus pneumonia, S. agalactiae, and Listeria monocytogenes; viruses such as Human Immunodeficiency Virus Type 1 (HIV-1), Human T-Cell Lymphotrophic Virus Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex, Herpesvirus 6, Herpesvirus 7, Epstein-Barr Virus, Cytomegalo-virus, Varicella-Zoster Virus, JC Virus, Parvovirus B19, Influenza A, B and C, Rotavirus, Human Adenovirus, Rubella Virus, Human Enteroviruses, Genital Human Papillomavirus (HPV), and Hantavirus; fungi such as Cryptococcus neoformans, Pneumocystis carinii, Histoplasma capsulatum, Blastomyces dermatitidis, Coccidioides immitis, and Trichophyton rubrum; and protozoa such as Trypanosoma cruzi, Leishmania sp., Plasmodium, Entamoeba histolytica, Babesia microti, Giardia lamblia, Cyclospora sp. and Eimeria sp. The method of the invention may also be used for Cryptosporidium oocyst detection; for identification of bacterial toxin genes, such as the toxin genes from Vibrio cholerae 01, enterotoxigenic Escherichia coli, Shigella sp., enteroinvasive E. coli, Helicobacter pylori (formerly Campylobacter pylori), toxigenic Clostridium difficile, Staphylococcus aureus, and Streptococcus pyogenes exotoxins; and for identification of anti-microbial resistance loci such as rifampin resistance mutations in Mycobacterium tuberculosis and M. leprae; HIV Drug Resistance, erm Erythromycin Resistance Genes, methicillin-resistance genes in Staphylococcus, Penicillinase-Producing genes in Neisseria gonorrhoeae, genes encoding aminoglycoside-modifying enzymes, genes encoding an extended spectrum of Beta-Lactamases, fluoroquinolone and isoniazid resistance mutations in Mycobacterium tuberculosis, and genes encoding vancomycin resistance in Enterococci.

In accordance with the method of the invention, a natural abundance DNA-containing sample suspected to contain the target microorganism is combined in a reaction mixture with (1) first and second primers that hybridize with the sense and antisense strands of the DNA of the target microorganism, respectively, and flank a selected region within the genome of the target microorganism, (2) a nucleotide triphosphate feedstock mixture, (3) at least one chain-terminating nucleotide triphosphate and (4) a polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides to form a reaction mixture. This reaction mixture is processed through a plurality of thermal cycles. Each thermal cycle includes at least an extension step which is performed at a temperature of around 68° to 75 °C. and a denaturation step performed at a temperature of around 90° to 98° C. In addition, the thermal cycles may include a separate annealing step performed at a temperature of 50° to 70° C.

During each cycle, the primers each anneal to the respective strand of any target DNA present in the sample, and primer chain extension using the polymerase enzymes and the nucleotide triphosphate feedstocks proceeds until terminated by incorporation of a chain-terminating nucleotide triphosphate. This results in the production of sequencing fragments comparable to those generated in a conventional sequencing reaction. Analysis of these fragments provides information concerning the sequence of the selected region of the target DNA, and thus of the serotype of the target microorganism. Those extension products which are not terminated prior to reaching the region complementary to the other primer can serve as template for generation of sequencing fragments in later cycles, although this generally occurs to a very small extent.

Among the advantages of the present invention is the ability to perform an evaluation directly on a "natural abundance" DNA sample. The nature of the initial sample will depend on the nature of the target microorganism. For example, in the case of Chlamydia, the initial sample employed in the present invention is suitably a urine sample, genital scraping or genital swab taken from a human patient, although other samples which are suspected of containing Chlamydia can also be tested using the method of the invention. Similarly, to test for HIV infection, the preferred sample is a blood sample.

The initial sample is treated to make DNA in the sample accessible for hybridization with the primers in the reaction mixture, for example by lysis, centrifugation to remove cell debris, and proteolytic digestion to expose the DNA. In accordance with the invention, it is not necessary to perform any type of preferential amplification of the target DNA in the sample prior to the use of the sample in the method of the invention, and indeed to reduce the number of steps and to simplify the assay it is preferred to use sample material which has not been previously subjected to any amplification procedure. As used in the specification and claims hereof, such sample materials in which the DNA in the sample has not been subjected to a preferential amplification step to increase one portion of the DNA relative to the remainder of the DNA will be referred to as "natural abundance samples."

Primers used in the method of the present invention can be any pair of primers which hybridize with the sense and antisense strands DNA of the target microorganism flanking a selected region of diagnostic relevance, and which do not both hybridize to neighboring locations in human DNA or other microbial DNA potentially found in the sample. As used herein, the term "flanking" will be understood to mean the positioning of primers at the 5'-ends of the selected region on each DNA strand, such that extension of the primers leads to replication of the region between the primers. The primers are preferably selected such that the primer pair flanks a region that is about 500 bp or less, although primers spanning larger regions of DNA can be utilized with adjustments to the sequencing mixture (generally an increase in the relative amount of deoxynucleotide triphosphates) to increase the amount of longer sequencing fragments produced.

Primers can be selected to hybridize with highly conserved regions which are the same in all variants of the target microorganism or can be prepared as degenerate primers to take known sequence variations at the primer site into account. Thus, the first and second primers of the invention may each be a discrete oligonucleotide species, or may be a set of oligonucleotide primers with similar but not identical sequences.

Primers can also be selected to bind to the sense and antisense strands of DNA flanking a region of the genome of the target microorganism which is constant across all known variants and forms of the microorganism, in which case the method of the invention would provide detection but not any specific qualitative characterization of the microorganisms, i.e., such primers could not provide discrimination between subspecies, serovars, strains, sub-types, biovars, variants, serotypes or between closely related species of the target microorganism. An example of such a primer pair is a primer pair that binds to the cryptic plasmid of C. trachomatis which is recognized as a suitably specific target sequence or detection purposes, but which is not known to vary from strain to strain. Preferably, however, the primers employed will flank a region of the target genome which is variable in sequence depending on the serotype of the organism. Thus, for C. trachomatis primers which flank portions of the omp1 gene are preferred. Similarly, in the case of HIV detection, primers flanking known mutation sites in the HIV protease gene or reverse transcriptase gene produce fragments which permit both detection of HIV and the identification of the HIV variant present in the sample. Primers MY09 and MY11 (See example 10) give sequence information for most relevant types of human papilloma virus (HPV) but not other viruses.

In an alternative embodiment, primer pairs are selected which, when treated under the conditions of the invention, give sequence information from a much wider variety of organisms. This is the case with eubacterial "universal" primers such as 91E and 13B listed in Appendix I which can be used to obtain sequence data from the 16S rDNA gene of many bacteria. These primers are useful for identifying which bacterium is present in a septic blood culture, or any other pure but unknown culture. Patient samples which contain a broad range of bacteria will give a complex result, consisting of many overlapping sequences when tested with these primers. The complex result may, in some cases, provide useful information about the bacteria present. However, in the normal course, it is advantageous to separate out the species, i.e. by plating them out first. In this case, individual pure colonies can be selected and identified.

In still another embodiment, the primer pairs are selected to determine whether a specific gene is present in the patient sample. The gene can be a toxin gene, a virulence gene, an anti-biotic resistance gene or a specific mutation which confers drug resistance or the like. Such a test can determine if a micro-organism is present and if it carries the gene at the same time.

Primers for other microorganisms can be derived from known sequence information. Appendix I lists a collection of suitable primer pairs for various other microorganisms which are taken from Persing et al., supra.

One or both of the primers may be labeled with a detectable label at the 5'-end thereof, particularly a fluorescent label such as fluorescein or a cyanine dye such as Cy 5.5. If labels are used on both primers, the labels selected should be spectroscopically-distinct, i.e., they should have either a different excitation spectrum or a different emission spectrum such that one primer can be distinguished from the other. When both primers are labeled with different detectable labels, the sequence of both strands of the sample can be determined in a single reaction.

The nucleotide triphosphate feedstock mixture is a standard mixture of the four conventional bases (A, C, G and T) in a buffer suitable for template-dependent primer extension with the enzyme employed. As will be appreciated by persons skilled in the art, the specific concentrations of the nucleotide triphosphates and the nature of the buffer will vary depending on the enzyme employed. Standard buffers and reagent concentrations for various known polymerase enzymes may be employed in the invention.

The reaction mixture used in the present invention also includes at least one type of chain-terminating nucleotide triphosphate. Separate reactions for the four different types of bases may be run either concurrently or successively. Running all four bases concurrently comports with conventional sequencing practice. However, a preferred embodiment of the present invention combines the single vessel methodology of this application with "single track sequencing" which is described in commonly assigned U.S. patent application Ser. No. 08/577,858. In single track sequencing, the determination of the positions of only one (or in any event less than 4) nucleotide(s) of a target sequence is frequently sufficient to establish the presence of and determine the qualitative nature of a target microorganism by providing a finger-print or bar-code of the target sequence that may be sufficient to distinguish it from all other known varieties of the sequence. Throughput is increased by reducing the number of reactions and electrophoresis runs required to identify a sequence. By selection of the order of bases tested, and intermediate analysis, it may be unnecessary to run all four bases to determine the presence and specific qualitative nature of any target microorganism present in the sample.

The polymerase enzyme used in the invention is a thermostable polymerase enzyme which incorporates dideoxynucleotides into an extending nucleic acid polymer at a rate which is no less than 0.4 times the rate of incorporation of deoxynucleotides. ThermoSequenase™ is exemplary of such an enzyme. Reeve et al., Nature 376: 796-797 (1995). Tabor et al. have also described enzymes which have increased processivity and increased levels of incorporation of dideoxynucleotides. (See EP-A1-0 655 506, which is incorporated herein by reference) Roche sells an enzyme under the trademark TAQ-FS which meets these criteria as well.

The absolute and relative amounts of nucleotide triphosphates and chain-terminating nucleotide triphosphates may be optimized for the particular enzyme employed. In general, however, the nucleotide triphosphates will be included at in the reaction mixture at concentrations of from 250 μM to 1.5 mM, and the chain-terminating nucleotide triphosphate will be included at a level of from 0.5 μM to 30 μM to produce compositions in which the mole ratio of the chain terminating nucleotide triphosphate to the corresponding nucleotide triphosphate is from 1:50 to 1:1000, preferably from 1:100 to 1:500. This will result in incorporation of a chain-terminating nucleotide triphosphate into from 30 to 100 percent of the extending polymer chains formed during the thermal cycling of the reaction mixture.

The method of the invention is suitably practiced using a kit which provides the appropriate reagents in conveniently packaged form. To reduce the number of sample preparation steps, and thus to reduce the risk of erroneous results, such a kit will suitably include at least one pre-prepared mixture comprising all four nucleotide triphosphates and at least one chain terminating nucleotide triphosphate, where the mole ratio of chain terminating nucleotide to the corresponding deoxynucleotide triphosphate is from 1:50 to 1:1000, preferably 1:100 to 1:500.

The invention will now be further described by way of the following non-limiting examples.

EXAMPLE 1

The presence of the sexually transmitted disease pathogen Chlamydia trachomatis in a patient sample is detected according to the method of the invention as follows.

Urine samples from patients suspected of carrying a sexually transmitted disease pathogen are prepared for sequence-based diagnosis as follows. 100 ul of first void urine are deposited in a sterile microcentrifuge tube. The tube is centrifuged at 12,000×g for 20 min; the supernatant is removed. 100 ul of Lysis Solution (Proteinase K @ 100 g/ml; 1% Tween 20) is added to the bacterial pellet and incubated 1 h at 55° C., or 18 h at room temperature. After a final incubation at 95° C. for 10 minutes, 200 ul of Geneclean II glass milk is added, according to the manufacturer's instructions. (Bio 101, Inc) DNA is eluted in 10 ul of double distilled H2 O. (A lysis solution control may be prepared if desired, by adding the lysis solution to a sterile tube (a tube without any urine pellet), and treating this tube like the others.)

The sample natural abundance DNA is then treated according to the method of the invention with a pair of primers and reagents to identify the sequence of a C. trachomatis gene present in the sample, if any. A suitable C. trachomatis specific target for sequencing is the cryptic plasmid. Primers that may be used are

______________________________________Name    Sequence______________________________________KL1:    TCCGGAGCGA GTTACGAAGA                        SEQ ID NO: 1!KL2:    ATTCAATGCC CGGGATTGGT                        SEQ ID NO: 2!______________________________________

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing (Mahony et al., "Confirmatory polymerase chain reaction testing for Chlamydia trachomatis in first void urine from asymptomatic and symptomatic men" J. Clin Microbiol. 30: 2241-2245 (1992)).

Either primer may be labeled at the 5'-end with a detectable label such as a Cy5.5 fluorophore. If both primers are labeled, they should be distinguishable. Labels are selected on the basis of the instrument employed for detection. Labeling reactions are performed according to methods well known in the art, such as amidite labeling or dye-ester condensation.

The sequencing reaction mixture is prepared by combining 2.5 ul of the prepared DNA sample, 0.67 ul of 10 uM primer KL1 (labeled with Cy5.5), 0.45 ul of KL2 primer at 10 uM, 2 ul of THERMOSEQUENASE reaction buffer (250 mM Tris-HCl pH 9.0 @25° C., 39 mM MgCl2), 2 ul of THERMOSEQUENASE enzyme (Amersham Life Sciences) diluted 1/10 in the dilution buffer provided with the enzyme and 5.38 ul of double distilled H2 O. The final volume is 13 ul.

3 ul of the sequencing reaction mixture is placed in each of 4 clean tubes and covered with one drop of mineral oil (Sigma Chemical Co., Cat # M-5904). The tube is placed in a PTC-100 thermal cycler (M.J. Research, Maine) and heated for 3 min at 94° C., then cooled to 85° C. One of the following termination mixtures are then added to each of the 4 tubes:

3 ul of dNTP:ddATP (1 mM each dNTP, 3.3 uM ddATP) in tube A.

3 ul of dNTP:ddCTP (1 mM each dNTP, 3.3 uM ddCTP) in tube C.

3 ul of dNTP:ddGTP (1 mM each dNTP, 3.3 uM ddGTP) in tube G.

3 ul of dNTP:ddTTP (1 mM each dNTP, 3.3 uM ddTTP) in tube T.

The dNTP:ddNTP mixes are preferably heated to 85° C. when added to the tube. The reaction mixture is mixed well and it is subjected to the following thermal cycling regime for 55 cycles:

94° C./30 sec.

60° C./30 sec.

70° C./1 min

After the last cycle, the tubes are kept at 70° C. for 2 min, then cooled to 4° C. until ready for loading. To view the reaction products, 6 ul of loading buffer (dye/stop solution) is added to each tube. The aqueous phase (the bottom phase disposed under the oil layer) is removed and put it in another tube. The sample is heated to 75° C. for 3 min, and put on ice. 2 ul of each sample is loaded in each well of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto, ON). The reaction products are electrophoretically separated and detected. The data is analyzed using GeneObjects software (Visible Genetics Inc., Toronto, ON) to base-call (i.e. determine the DNA sequence) of the samples. The base-called sequence is compared to the known C. trachomatis sequence to confirm diagnosis. Results are reported to the patient file.

EXAMPLE 2

The method of the invention may be employed to identify not only the presence of C. trachomatis in a patient sample but also the strain identity. Health care workers currently seek to distinguish among Chlamydia trachomatis strains to determine the molecular epidemiologic association of a range of diseases with infecting genotype (See Dean, D. et al "Major Outer Membrane Protein Variants of Chlamydia trachomatis Are Associated with Severe Upper Genital Tract Infections and Histopathology in San Francisco." J. Infect. Dis. 172: 1013-22 (1995)).

A suitable strain specific target for C. trachomatis is the omp1 (outer membrane protein) gene which has at least 4 variable sequence ("VS") domains that may be used to distinguish among the 15 known genotypes of C. trachomatis (Yuan, Y. et al. "Nucleotide and Deduced Amino Acid Sequences for the Four Variable Domains of the Major Outer Membrane Proteins of the 15 Chlamydia trachomatis Serovars" Infect. Immun. 57 1040-1049 (1989)).

Strain identification is achieved using the method of Example 1 with the following modifications. First of all, because of the length of the VS domains, separate reactions are performed to obtain sequence from VS1/VS2 and VS3/VS4. The following oligonucleotide primers may be employed:

______________________________________For VS1/VS2:Name  Sequence______________________________________MF21  CCGACCGCGT CTTGAAAACA GATGT                         SEQ. ID NO. 3!MB22  CACCCACATT CCCAGAGAGC T                         SEQ. ID NO. 4!For VS3/VS4Name  SequenceMVF3  CGTGCAGCTT TGTGGGAATG T                         SEQ. ID NO. 5!MB4   CTAGATTTCA TCTTGTTCAA TTGC                         SEQ. ID NO. 6!______________________________________

These sequencing primers were employed previously for PCR amplification reactions, but not sequencing. Mahoney et al., supra.

These oligonucleotide primers are used in separate reactions in place of KL1 and KL2 in Example 1. The sample preparation and sequencing reactions are performed as in Example 1. The reaction products are electrophoretically separated and detected on a MicroGene Blaster automated DNA sequencing apparatus (Visible Genetics Inc., Toronto, ON). The data is analyzed using GeneObjects software to base-call the samples and to compare the data to the known varieties of C. trachomatis. Pure populations generally give unambiguous sequence data. Where heterozygous mixed populations are detected, a circumstance thought to occur in 1-3% of clinical C. trachomatis samples, the software identifies the strains which could be combined to result in the particular heterozygote sample detected.

EXAMPLE 3

Strain-specific C. trachomatis identification over the VS1/VS2 domain can be achieved according to the method in Example 1, by using the following degenerate primers sets:

______________________________________ForwardOMP291: AGCATGCGTR TKGGTTACTA YGG                         SEQ ID NO. 7!(labeled with Cy5.5). Base 175 to 197 of the ORF of the omplgene of C. trachomatis.ForwardOMP314A:   TGACTTTGTT TTCGACCGYG TTTT                         SEQ ID NO. 8!(labeled with Cy5.5). Base 198 to 221 of the ORF of the omplgene of C. trachomatis.ReverseOMP722: CTAAAGTYGC RCATCCACAT TCC                         SEQ ID NO. 9!Base 637 to 615 of the ORF of the ompl (in serovar K) gene of C.trachomatis. The primer may not have the EXACT SAME sequence asin serovar K.ReverseOMP711: CATCCACATT CCCASARAGC TGC                         SEQ ID NO. 10!Base 626 to 604 of the ORF of the ompl (in serovar K) gene of C.trachomatis. The primer may not have the exact same sequence asin serovar K.______________________________________

These primers sets are preferably used in the following combinations:

(1) OMP291-OMP722, sequencing a 455 to 463-bp (depending on the serotype) fragment of the omp1 gene of C. trachomatis; or

(2) OMP314A-OMP711, sequencing a 421 to 430-bp (depending on the serotype) fragment of the omp1 gene of C. trachomatis.

EXAMPLE 4

The method as exemplified in Examples 1, 2 and 3 may be further improved by employing different labels, preferably fluorescent labels, on the different primers for use in a multi-dye sequencer. This method takes advantage of the fact that a given termination mixture containing, for example, ddATP will give chain termination products for the A nucleotide in both directions. The different primer labels means that one reaction mixture loaded in a single lane of an automated DNA sequencing apparatus designed to detect the two labels (a "multi-dye sequencer") will identify the A nucleotide of both sense and antisense strands. Separate reactions are performed for the other 3 nucleotides. Using only 4 lanes of an electrophoresis gel, and 4 reaction mixtures, the DNA sequences of both the sense and anti-sense strands can be obtained. This information allows the operator to resolve any ambiguities that may be present.

Use of two different labels lends itself to a further improvement. As noted above, in a reaction according to the invention, the results of the ddATP reaction will give chain termination products for the A nucleotide in both directions. Since the A nucleotide in one direction corresponds to the T nucleotide in the other, a single reaction can provide the location of two bases. A second termination reaction with, for example, ddCTP will then obtain the positions of the other two nucleotides, C and G. Thus only two lanes of an electrophoresis gel and 2 reaction mixtures are required to identify the location of all 4 bases of the sequence.

A suitable multi-dye sequencer for use with this aspect of the invention, is the Applied Biosystems 377 Prism automated DNA sequencer (Applied Biosystems Inc., Foster City, Calif.). The fluorescent labels are selected to be detectable on the 377 instrument. Instead of the dye-terminator chemistry suggested in the Applied Biosystems product literature, however, the fluorescent labels must be conjugated to the 5' end of the primer molecules. The samples are electrophoresed, detected and the detected data is recorded.

Sophisticated software such as GeneObjects software (Visible Genetics Inc, Toronto, CA) may be used to assist in evaluation of the results. This software may employ the methods of commonly assigned U.S. patent applications Ser. Nos. 08/497,202 and 08/670,534 and International Patent Application No. PCT/US96/11130, all of which are incorporated herein by reference. In one of the methods, the single nucleotide data tracks are evaluated and nucleotides are positioned relative to the known (or standard) DNA sequence expected from the sample. When data tracks are generated for each of the four nucleotides, the full DNA sequence of the sample may be base-called. The base-called sequence is then compared to the library of known sequences to determine which C. trachomatis strain or strains are present in the sample.

EXAMPLE 5

The sequence of both the sense strand and antisense strand of a C. trachomatis cryptic plasmid gene may be obtained in a one step reaction using the primers:

______________________________________Name    Sequence______________________________________KL1:    TCCGGAGCGA GTTACGAAGA                        SEQ ID NO. 1!CT1590: ATGCCCGGGA TTGGTTGATC                        SEQ ID NO. 11!______________________________________

Combine the following materials and mix well:

______________________________________             Concentration                      Amount______________________________________Patient Sample DNA                 11.25                                   ulKL1*Cy5.5 Primer    10    uM       3    ulCT1590*Fluoresceine Primer               10    uM       2    ulEnzyme Diluent (Amersham plc)      8    ulThermoSequenase Enzyme               32    U/ul     0.9  uldouble distilled H2 O         24.2 ul______________________________________

Take 11 ul of the mixture and add 2 ul of 13×buffer Tris-HCl 260 mM pH 8.3, MgCl2 39 mM! (final concentration 20 mM Tris-HCl pH 8.3, 3 mM MgCl2). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94° C. for 5 mins then reduce temperature to 85° C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94° C. for 10 sec, 62° C. for 15 sec, 70° C. for 1 min. Upon completion, treat the mixture for a final 5 min at 70° C. and then store at 4° C. until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a colored dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labeled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects Software. The base-calling results of the Cy5.5 labeled primer were compared to the known sequence of the gene by the GeneLibrarian component of GeneObjects.

EXAMPLE 6

As described in U.S. patent application Ser. No. 08/577,858, not all 4 nucleotides of C. trachomatis, or any polymorphic or multiple allelic locus of any gene or organism necessarily need to be determined in order to ascertain which allele or variant is present. In many cases, positioning less than four nucleotides may be sufficient to determine with certainty which allele is present. The method of Examples 1-4 may be modified to obtain single nucleotide data tracks (or fragment patterns) by performing only one of the termination reactions at a time.

In the case of detection and serotyping of C. trachomatis, the evaluation of the A track alone over the first 100 nucleotides of the omp1 gene, aligning to nucleotides 249-349 of the serovars C and K, can distinguish the serovars. Appendix II is a text file representation of the omp1 gene in each of the serovars. The sequences are all aligned to the last (3') nucleotide of the detectably labeled primer omp314A. (Appendix II shows sequences starting 29 bp downstream of the 3'-nucleotide.) This illustration differs from a traditional "consensus" sequence illustrations in that all missing bases (usually represented by N's or raised dashes) are deleted. The A's are illustrated in the order and positions in which they would be expected to appear after a sequencing reaction and upon detection by an automated DNA electrophoresis apparatus.

If, in another microorganism, the A lane (or other preferred first lane) were not sufficient to distinguish all types, a second reaction for the C, G or T nucleotide could be performed to further define the qualitative nature of any target microorganism present in the sample. Because the sequences of the types are previously known, the operator can determine which of the nucleotides provide the greatest information and will analyze those nucleotides first.

EXAMPLE 7

The presence of and strain identity of C. trachomatis in a patient sample may be determined according to the methods of the previous examples by substituting the following primer pairs. These primers are used to determine the sequence of the omp1 gene (publicly available at DNASIS Accession No. X62921). Forward Primer (5' Primer) labeled with a detectable label such as Cy5.5:

______________________________________Primer OMP312: GGAGACTTTG TTTTCGACCG                    SEQ ID NO 12!Position 312-331 of X62921______________________________________

and one of the following Reverse Primers (3' Primer) (optionally labeled with a detectable label different from the 5' primer):

______________________________________Primer OMP708: CATTCCCACA AAGCTGCGCG                    SEQ ID NO 131Position 727-708 of X62921Primer OMP706: TTCCCACAAA GCTGCGCGAG                    SEQ ID NO 14!Position 725-706 of X62921Primer OMP704: CCCACAAAGC TGCGCGAGCG                    SEQ ID NO 15!Position 723-704 of X62921______________________________________

The following combination can be used to obtain DNA sequence over the following maximum lengths: OMP312-OMP708: 416-nt region of omp1 OMP312-OMP706: 414-nt region of omp1 OMP312-OMP704: 412-nt region of omp1

EXAMPLE 8

The presence of and strain identity of C. trachomatis in a patient sample may be determined according to the method of previous examples, using C. trachomatis ribosomal DNA (rDNA) specific primers such as

______________________________________CT220 ACCTTTCGGT TGAGGGAGAG TCTA                        SEQ ID NO 16!andCT447 GGACCAATTC TTATTCCCAA GCGA                        SEQ ID NO 17!______________________________________

Haydock et al., Chap 1.10 in Persing et al., supra.

EXAMPLE 9

The sequence of both the sense strand and antisense strand of the protease gene of HIV-1 integrated into natural abundance DNA of lymphocytes may be obtained in a one step reaction as follows.

Natural abundance DNA is prepared from the patient blood lymphocyte sample according to a standard method such as a standard salting-out procedure (as provided by the Puregene DNA Isolation Kit, Gentra Systems, Inc., Minneapolis) or by detergent and proteinase K treatment (Current Protocols in Molecular Biology, Eds. Ausubel, F. M. et al, (John Wiley & Sons; 1995)).

Combine the following materials and mix well:

______________________________________             Concentration                      Amount______________________________________Patient Sample DNA                 11.25                                   ulPR211F*Cy5.5 Primer 10    uM       3    ulorPR281*Cy5.5 Primer  10    uM       3    ulPR526*Fluorescein Primer               10    uM       2    ulEnzyme Diluent (Amersham plc)      8    ulTHERMOSEQUENASE Enzyme               32    U/ul     0.9  uldouble distilled H2 O         24.2 ul______________________________________

The primers have the following sequences:

______________________________________Name  Sequence______________________________________Choice of Forward PrimersPR211F ATCACTCTTT GGCAACGACC  SEQ ID No. 18!(FORWARD), BASE 6 TO 25 OF THE PROTEASE GENEPR281 CAGGAGCAGA TGATACAGTA TTAG                        SEQ ID No. 19!(FORWARD), BASE 76 TO 99 OF THE PROTEASE GENEReverse PrimerPR526: CCATTCGTGG CTTTAATTTT ACTGG                        SEQ ID No. 20!(REVERSE), BASES 321 TO 345 OF THE PROTEASE GENE______________________________________

PR211F-PR526 creates a sequencing fragment of maximum size 340 bp. PR281-PR526 creates a sequencing fragment of maximum size 270 bp. Both regions contain the sequence of the various codons where mutations are involved in protease inhibitor resistance (Codons 46, 48, 54, 63 82 84 and 90).

Take 11 ul of the mixture and add 2 ul of 13× buffer Tris-HCl 260 mM pH 8.3, MgCl2 39 mM! (final concentration 20 mM Tris-HCl pH 8.3, 3 MM MgCl2). Mix well and place 3 ul into each of 4 tubes. Heat tube to 94° C. for 5 mins then reduce temperature to 85° C. Add and mix 3 ul of an 85 C dNTP/ddNTP solution consisting of 0.75 mM each dNTP and 2.5 uM of a chain terminating nucleotide triphosphate (ddNTP) (use a different ddNTP in each of the 4 tubes).

Treat the mixture to 60 cycles of the following thermal cycling reactions: 94 C. for 10 sec, 62 C. for 15 sec, 70 C. for 1 min. Upon completion, treat the mixture for a final 5 min at 70 C. and then store at 4 C. until ready for loading. For viewing the reaction products, add an equal volume of stop/loading solution (95% formamide plus a coloured dye). Take 1.5 ul and load in a single lane of a MicroGene Blaster automated DNA sequencer (Visible Genetics Inc., Toronto). Load the remaining mixture (@ 10.5 ul) in a single lane of an ALF Automated Sequencer (Pharmacia LKB, Uppsala, Sweden). The reaction products from the Cy5.5 labelled primer are detected on the MicroGene Blaster using GeneObjects Software. The reaction products from the fluorescein labeled primer are detected on the ALF Automated Sequencer using GeneObjects Software. The base-called results from each primer were compared to the known sequences of HIV-1 by GeneLibrarian (a component of GeneObjects (Visible Genetics Inc, Toronto).

EXAMPLE 10

The presence and type of human papilloma virus (HPV) present in a patient sample can be determined according to the method of the invention by following the protocol in Example 1 with the following modifications.

Patient sample DNA is extracted from 250 ul urine specimens using Geneclean II (Bio 101, Inc.). The sample is then treated as described previously but employing the degenerate primer pair:

______________________________________Forward Primer: MY11GCMCAGGGWC ATAAYAATGG   SEQ ID No. 21!Reverse Primer: MY09CGTCCMAARG GAWACTGATC   SEQ ID NO. 22)______________________________________

The reactions are performed as before, using ThermoSequenase enzyme or the like. Reaction products are detected on an automated electrophoresis/detection device such as the MicroGene Blaster. The sequence is analyzed and compared to the known varieties of HPV to identify the type. The result is reported to the patient file.

                                  APPENDIX I__________________________________________________________________________Suitable Sequencing Primer Pairs for Identification andSub-Typing of Infectious Pathogenscf. Diagnostic Molecular Microbiology (Eds. Persing et al.)(1993; American Society for Microbiology; Washington D.C.)__________________________________________________________________________Bacterial Pathogens Universal (16S rDNA) Typing PrimersPathogen Name: Universal Bacterial IdentificationGene: 16s rDNAForward Primer: 91ETCAAAKGAAT TGACGGGGGC       SEQ ID No. 23!Site of Specific Hybridization: nt 911-930Reverse Primer: 13BAGGCCCGGGA ACGTATTCAC       SEQ ID No. 24!Site of Specific Hybridization: nt 1390-1371Maximum fragment size: 475 ntPathogen Name: Universal Bacterial IdentificationGene: 16s rDNAForward Primer: 515FPLTGCCAGCAGC CGCGGTAA         SEQ ID No. 25!Site of Specific Hybridization: nt 515-533Reverse Primer: 806RGGACTACCAG GGTATCTAAT       SEQ ID No. 26!Site of Specific Hybridization: nt 806-787Maximum fragment size: 328 ntPathogen Name: Universal Bacterial IdentificationGene: 16s rDNAForward Primer: 11EGAGGAAGGTG GGGATGACGT       SEQ ID No. 27!Site of Specific Hybridization: nt 1175-1194Reverse Primer: 13BAGGCCCGGGA ACGTATTCAC       SEQ ID No. 28!Site of Specific Hybridization: nt 1390-1371Maximum fragment size: 233 ntPathogen Name: Eubacterial Typing (Broad range of eubacteria)Gene: 16S rDNAForward Primer: 285GAGAGTTTGA TCCTGGCTCA G     SEQ ID No. 29!Site of Specific Hybridization: nt 9-30Reverse Primer: 244CCCACTGCTG CCTCCCGTAG       SEQ ID No. 30!Site of Specific Hybridization: nt 341-361Maximum fragment size: 352 bpBacteriaPathogen Name: Mycobacteria Typing (M. tuberculosis complex)Gene: 16S rDNAForward Primer: 285GAGAGTTTGA TCCTGGCTCA G     SEQ ID No. 31!Site of Specific Hybridization: nt 9-30Reverse Primer: 259TTTCACGAAC AACGCGACAA       SEQ ID No. 32!Site of Specific Hybridization: nt 590-609Maximum fragment size: 600 bpPathogen Name: Mycobacterium tuberculosisGene: IS6110Forward Primer: T5CTCGTCCAGC GCCGCTTCGG       SEQ ID No. 33!Site of Specific Hybridization: nt 758-788Reverse Primer: T4CCTGCGAGCG TAGGCGTCGG       SEQ ID No. 34!Site of Specific Hybridization: nt 881-862Maximum fragment size: 123 bpPathogen Name: Rickettsia rickettsii (Rocky Mountain spottedfever)Gene: 17 K Da Ag GeneForward Primer: TZ15TTCTCAATTC GGTAAGGC         SEQ ID No. 35!Site of Specific Hybridization: nt 191-209Reverse Primer: TZ16ATATTGACCA GTGCTATTTC       SEQ ID No. 36!Site of Specific Hybridization: nt 437-419Maximum fragment size: 247 bpPathogen Name: Ehrlichia chaffeensisGene: 16s rDNAForward Primer: HE1CAATTGCTTA TAACCTTTTG GTTATAAAT                       SEQ ID No. 37!Site of Specific Hybridization: nt 49-77Reverse Primer: HE3TATAGGTACC GTCATTATCT TCCCTAT                       SEQ ID No. 38!Site of Specific Hybridization: nt 438-412Maximum fragment size: 390 bpPathogen Name: Borrelia burgdorferi (Lyme disease)Gene: Outer Surface Protein AForward Primer: OSPA149TTATGAAAAA ATATTTATTG GGAAT                       SEQ ID No. 39!Site of Specific Hybridization: nt 1Reverse Primer: OSPA319CTTTAAGCTC AAGCTTGTCT ACTGT                       SEQ ID No. 40!Site of Specific Hybridization: nt 193Maximum fragment size: 193 bpPathogen Name: Borrelia burgdorferi (Lyme disease)Gene: Outer Surface Protein AForward Primer: OSPA4CTGCAGCTTG GAATTCAGGC ACTTC                       SEQ ID No. 41!Site of Specific Hybridization: nt 638Reverse Primer: OSPA2GTTTTGTAAT TTCAACTGCT GACC  SEQ ID No. 42!Site of Specific Hybridization: nt 793Maximum fragment size: 156 bpPathogen Name: Borrelia burgdorferi (Lyme disease)Gene: 16s rDNAForward Primer: DD06ATCTGTTACC AGCATGTAAT       SEQ ID NO. 43!Site of Specific Hybridization: nt 1105Reverse Primer: DD02CCCTCACTAA ACATACCT         SEQ ID No. 44!Site of Specific Hybridization: nt 1472Maximum fragment size: 368 bpPathogen Name: Borrelia burgdorferi (Lyme disease)Gene: FlagellinForward Primer: FLA1GATGATGCTG CTGGCATGGG AGTTTCTGG                       SEQ ID No. 45!Site of Specific Hybridization: nt 121Reverse Primer: FLA3CTGTCTGCAT CTGAATATGT GCCGTTACCT G                       SEQ ID No. 46!Site of Specific Hybridization: nt 320Maximum fragment size: bpPathogen Name: Yersinia pestis (the bubonic plague)Gene: 9.5 kb pesticin plasmidForward Primer: Yp1ATCTTACTTT CCGTGAGAAG       SEQ ID No. 47!Site of Specific Hybridization: nt 971-990Reverse Primer: Yp2CTTGGATGTT GAGCTTCCTA       SEQ ID No. 48!Site of Specific Hybridization: nt 1450-1431Maximum fragment size: 478 bpPathogen Name: Treponema pallidum (venereal syphilis)Gene: 47-kDA geneForward Primer: 47-3TTGTGGTAGA CACGGTGGGT AC    SEQ ID No. 49!Site of Specific Hybridization: nt 692-713Reverse Primer: 47-4TGATCGCTGA CAAGCTTAGG CT    SEQ ID No. 50!Site of Specific Hybridization: nt 1187-1166Maximum fragment size: 496 bpPathogen Name: Treponema pallidum (venereal syphilis)Gene: 16S rDNAForward Primer: Tpr3CTCAGAGATG AGCCTGCGAC CATT  SEQ ID NO. 51!Site of Specific Hybridization: nt 230Reverse Primer: TPr4GCATTCCCTC CCGTCCTCAT TCTTC                       SEQ ID No. 52!Site of Specific Hybridization: nt 480Maximum fragment size: 251 bpPathogen Name: Chlamydia trachomatis (infection of mucosalsurfaces)Gene: MOMPForward Primer: CT.0005GATAGCGAGC ACAAAGAGAG CTAA  SEQ ID No. 53!Site of Specific Hybridization: nt 67Reverse Primer: CT.06TTCACATCTG TTTGCAAAAC ACGGTCGAAA ACAAAG                       SEQ ID No. 54!Site of Specific Hybridization: nt 347Maximum fragment size: 281 bpPathogen Name: Chlamydia pneumoniae (respiratory disease)Gene: 474bp PST fragmentForward Primer: HL-1GTTGTTCATG AAGGCCTACT       SEQ ID No. 55!Site of Specific Hybridization: nt 30-49Reverse Primer: HR-1TGCATAACCT ACGGTGTGTT       SEQ ID No. 56!Site of Specific Hybridization: nt 467-448Maximum fragment size: 438 bpPathogen Name: Mycoplasma pneumoniae (respiratory disease)Gene: genomicForward Primer: MP5-1GAAGCTTATG GTACAGGTTG G     SEQ ID No. 57!Reverse Primer: MP5-2ATTACCATCC TTGTTGTAAG       SEQ ID No. 58!Maximum fragment size: 144 bpPathogen Name: Mycoplasma speciation (Universal Primers for 8most common Mycoplasma species)Gene: 16S rDNAForward Primer: Primer AGGCGAATGGG TGAGTAACAC G     SEQ ID No. 59!Site of Specific Hybridization: nt 87Reverse Primer: Primer BCGGATAACGC TTGCGACCTA TG    SEQ ID No. 60!Site of Specific Hybridization: nt 550Maximum fragment size: 464 bpPathogen Name: Legionella pneumophila (wound infection,respiratory disease)Gene:Forward Primer: LEG1GCTATGAGGA ATCTCGCTG        SEQ ID No. 61!Reverse Primer: LEG2CTGGCTTCTT CCAGCTTCA        SEQ ID No. 62!Maximum fragment size: 800 bpPathogen Name: Legionella dumoffii (wound infection, respiratorydisease)Gene:Forward Primer: LDBKS1ATACACGTGG TGGAGGTAC        SEQ ID No. 63!Reverse Primer: LDBKS2GCGGGCAATA TCTTGCATC        SEQ ID No. 64!Maximum fragment size: 1000 bpPathogen Name: Mycoplasma fermentansGene: IS-like elementForward Primer: RW005GGTTATTCGA TTTCTAAATC GCCT  SEQ ID No. 65!Site of Specific Hybridization: nt 1116Reverse Primer: RW004GGACTATTGT CTAAACAATT TCCC  SEQ ID No. 66!Site of Specific Hybridization: nt 1321Maximum fragment size: 206 ntPathogen Name: EhrlichiaGene: 16S rDNAForward Primer: 8FAGTTTGATCA TGGCTCAG         SEQ ID No. 67!Site of Specific Hybridization: nt 32Reverse Primer: GA1URGAGTTTGCCG GGACTTCTTC T     SEQ ID No. 68!Site of Specific Hybridization: nt (about 400)Maximum fragment size: (about 400 nt)VirusesHuman Immunodeficiency Virus Type 1 (HIV-1)Gene: gagForward Primer: SK462AGTTGGAGGA CATCAAGCAG CCATGCAAAT                       SEQ ID No. 69!Site of Specific Hybridization 1366-1395: ntReverse Primer: SK431TGCTATGTCA GTTCCCCTTG GTTCTCT                       SEQ ID No. 70!Site of Specific Hybridization: nt 1507-1481Maximum fragment size: 142 ntHuman T-Cell Lymphotrophic Virus Type 1 (HTLV-1)Gene: POLForward Primer: POL1CCCGGGCCCC CTGACTTGTC       SEQ ID No. 71!Site of Specific Hybridization: nt 2802-2821Reverse Primer: POL3GCTTTCACTG TCCCACAGCAG      SEQ ID No. 72!Site of Specific Hybridization: nt 2916-2936Maximum fragment size: 237 ntHepatitis B Virus (HBV)Gene: surface antigenForward Primer: Primer 1CAAGGTATGT TGCCCGTTTG       SEQ ID No. 73!Site of Specific Hybridization: nt 329-348Reverse Primer: Primer 2AAAGCCCTGC GAACCACTGA       SEQ ID No. 74!Site of Specific Hybridization: nt 587-568Maximum fragment size: 259 ntHepatitis C Virus (HCV)Gene: 5'UTForward Primer: 5PUT c1-aCCCAACACTA CTCGGCTAG        SEQ ID No. 75!Site of Specific Hybridization: nt -74--92Reverse Primer: 5PUT 1-sAACTACTGTC TTCACGCAGA AAGC  SEQ ID No. 76!Site of Specific Hybridization: nt -266--289Maximum fragment size: 216 ntHerpes simplex virus (HSV)Gene: DNA polymerase geneForward Primer: HSV-3TACATCGGCG TCATCTGCGG GG    SEQ ID No. 77!Site of Specific Hybridization: nt 2821-2842Reverse Primer: HSV-4CAGTTCGGCG GTGAGGACAA AG    SEQ ID No. 78!Site of Specific Hybridization: nt 3090-3111Maximum fragment size: 290 ntHerpesvirus 6Gene:Forward Primer: H6-6AAGCTTGCAC AATGCCAAAA AACAG                       SEQ ID No. 79!Reverse Primer: H6-7CTCGAGTATG CCGAGACCCC TAATC                       SEQ ID No. 80!Maximum fragment size: 223 ntHerpesvirus 7Gene:Forward Primer: HV7TATCCGAGCT GTTTTCATAT AGTAAC                       SEQ ID No. 81!Reverse Primer: HV8GCCTTGCGGT AGCACTAGAT TTTTTG                       SEQ ID No. 82!Maximum fragment size: 186 ntEpstein-Barr VirusGene: EBNA2Forward Primer: E2p1AAGGATGCCT GGACACAAGA       SEQ ID No. 83!Site of Specific Hybridization: nt 1813-1833Reverse Primer: E2p2TGGTGCTGCT GGTGGTGGCA AT    SEQ ID No. 84!Site of Specific Hybridization: nt 2409-2388Maximum fragment size: 596 ntCytomegalovirus (CMV) (member of Herpesviridae)Gene: CMV IE geneForward Primer: CMV1CCTAGTGTGG ATGACCTACG GGCCA                       SEQ ID No. 85!Site of Specific Hybridization: nt 1234-1258Reverse Primer: CMV2CAGACACAGT GTCCTCCCGC TCCTC                       SEQ ID No. 86!Site of Specific Hybridization: nt 1459-1483Maximum fragment size: 249 ntVaricella-Zoster Virus (VZV) (for Chicken Pox)Gene: unique genomic fragmentForward Primer: VZ7ATGTCCGTAC AACATCAACT       SEQ ID No. 87!Site of Specific Hybridization: nt 3377-3396Reverse Primer: VZ8CGATTTTCCA AGAGAGACGC       SEQ ID No. 88!Site of Specific Hybridization: nt 3643-3624Maximum fragment size: 267 ntJC Virus (JCV) distinguishing from BK virus and simian virus 40Gene: T antigenForward Primer: P5AGTCTTTAGG GTCTTCTACC       SEQ ID No. 89!Site of Specific Hybridization: nt 4255-4274Reverse Primer: P6GGTGCCAACC TATGGAACAG       SEQ ID No. 90!Site of Specific Hybridization: nt 4427-4408Maximum fragment size: 172 ntParvovirus B19Gene: VP ProteinForward Primer: ZGGAACAGACT TAGAGCTTAT TC    SEQ ID No. 91!Site of Specific Hybridization: nt 2537Reverse Primer: YGCTTGTGTAA GTCTTCACTA G     SEQ ID No. 92!Site of Specific Hybridization: nt 2774Maximum fragment size: 259 ntInfluenza A (Orthomyxoviridae)Gene: hemagglutinin H2Forward Primer: AH2BCAATAGCTGG TTTTATAGAA       SEQ ID No. 93!Site of Specific Hybridization: nt 1077Reverse Primer: AH2CIITTATCATACA GATTCTTGAC       SEQ ID No. 94!Site of Specific Hybridization: nt 1425Maximum fragment size: 349 ntInfluenza B (Orthomyxoviridae)Gene: Matrix ProteinForward Primer: BMPBGAAGGCAAAG CAGAACTAGC       SEQ ID No. 95!Site of Specific Hybridization: nt 79Reverse Primer: BMPCIITGGCCTTCTG CTATTTCAAA       SEQ ID No. 96!Site of Specific Hybridization: nt 380Maximum fragment size: 302 ntInfluenza C (Orthomyxoviridae)Gene: hemagglutininForward Primer: CHABGTGCAAACTG CATCTTGTGG       SEQ ID No. 97!Site of Specific Hybridization: nt 705Reverse Primer: CHACIICTCATTTCTT GATCTCCATG       SEQ ID No. 98!Site of Specific Hybridization: nt 1145Maximum fragment size: 441 ntRotavirusGene: vp7Forward Primer: A2GGACCAAGAG AAAACGTAGC       SEQ ID No. 99!Site of Specific Hybridization: nt 805Reverse Primer: A4GGTCACATCA TACAATTCTA ATCTAAG                       SEQ ID No. 100!Site of Specific Hybridization: nt 1062Maximum fragment size: 257 ntHuman AdenovirusGene: Hexon geneForward Primer: A2H/pcr 4RATGACTTTTG AGGTGGATCC CATGGA                       SEQ ID No. 101!Reverse Primer: A2H/pcr 1GCCGAGAAGG GCGTGCGCAG GTA   SEQ ID No. 102!Maximum fragment size: 134 ntRubella VirusGene: 40S ssRNAForward Primer: Ru2TGCTTTGCCC CATGGGACCT CGAG  SEQ ID No. 103!Site of Specific Hybridization: nt 1990-2013Reverse Primer: Ru3GGCGAACACG CTCATCACGG T     SEQ ID No. 104!Site of Specific Hybridization: nt 2310-2290Maximum fragment size: 321 ntHuman EnterovirusesGene: 5'NTRForward Primer: MD91CCTCCGGCCC CTGAATGCGG CTAAT                       SEQ ID No. 105!Site of Specific Hybridization: nt 444-468Reverse Primer: MD90ATTGTCACCA TAAGCAGCCA       SEQ ID No. 106!Site of Specific Hybridization: nt 577-596Maximum fragment size: 154 ntGenital Human Papillomavirus (HPV)Gene: L1 geneForward Primer: MY11GCMCAGGGWC ATAAYAATGG       SEQ ID No. 107!Site of Specific Hybridization: nt 6582Reverse Primer: MY09CGTCCMAARG GAWACTGATC       SEQ ID No. 108!Site of Specific Hybridization: nt 7033Maximum fragment size: 450 ntHantavirusGene: M segmentForward Primer: Har M 30+CACTGAATAA GAGGATACAA GAATGG                       SEQ ID No. 109!Site of Specific Hybridization: nt 30Reverse Primer: Har M 403-GGAGGAATAT TACATGTGCC TTT   SEQ ID No. 110!Site of Specific Hybridization: nt 403Maximum fragment size: 374 ntFungiCryptococcus neoformans (Universal fungal primers)Gene:Forward Primer: ITS1TCCGTAGGTG AACCTGCGA        SEQ ID No. 111!Reverse Primer: ITS4TCCTCCGCTT ATTGATATGC       SEQ ID No. 112!Maximum fragment size: 600 ntPneumocystis cariniiGene: 5S rDNAForward Primer: 5S SenseAGTTACGGCC ATACCTCAGA       SEQ ID No. 113!Reverse Primer: 5S AntisenseAAAGCTACAG CACGTCGTAT       SEQ ID No. 114!Maximum fragment size: 120 ntFungal Pathogens (Histoplasma capsulatum, Blastomycesdermatitidis, Coccidioides immitis Trichophyton rubrum)Gene: 18S rDNAForward Primer: NS3GCAAGTCTGG TGCCAGCAGC C     SEQ ID No. 115!Site of Specific Hybridization: nt 551Reverse Primer: RDR116CCGTCAATTC CTTTATGTTT CAGCCTT                       SEQ ID No. 116!Site of Specific Hybridization: nt 1149Maximum fragment size: 599 ntProtozoaTrypanosoma cruziGene: kinetoplaseForward Primer: S35AAATAATGKA CGGGTGAGAT GCATGA                       SEQ ID No. 117!Reverse Primer: S36GGGTTCGATT GGGGTTGGTG T     SEQ ID No. 118!Maximum fragment size: 330 ntLeishmania speciesGene: kinetoplastForward Primer: 13AGTGGGGGAGG GGCGTTCT         SEQ ID No. 119!Reverse Primer: 13BATTTTACACC AACCCCCAGT T     SEQ ID No. 120!Maximum fragment size: 120 ntPlasmodium (genus specific)Gene: Nuclear small subunit rDNAForward Primer: 566RGGATAACTAC GGAAAAGCTG TAGC  SEQ ID No. 121!or Forward Primer: 570RCGACTTCTCC TTCCTTTAAA AGATAGG                       SEQ ID No. 122!Reverse Primer: 567RGTTCAAGATT AATAATTGCA ATAATCTATC CC                       SEQ ID No. 123!Maximum fragment size: about 500 ntEntamoeba histolytica (amoebic dysentery)Gene: SSU rDNAForward Primer: Psp5GGCCAATTCA TTCAATGAAT TGAG  SEQ ID No. 124!Site of Specific Hybridization: nt 200Reverse Primer: Psp3CTCAGATCTA GAAACAATGC TTCTC                       SEQ ID No. 125!Site of Specific Hybridization: nt 1075Maximum fragment size: 876 ntBabesia microtiGene: SS rDNAForward Primer: Bab1CTTAGTATAA GCTTTTATAC AGC   SEQ ID No. 126!Site of Specific Hybridization: nt 38-60Reverse Primer: Bab4ATAGGTCAGA AACTTGAATG ATACA                       SEQ ID No. 127!Site of Specific Hybridization: nt 251-275Maximum fragment size: 238 ntGiardia lambliaGene: 18S rDNA geneForward Primer: JW1GCGCACCAGG AATGTCTTGT       SEQ ID No. 128!Site of Specific Hybridization: nt 1251-1270Reverse Primer: JW2TCACCTACGG ATACCTTGTT       SEQ ID No. 129!Site of Specific Hybridization: nt 1433-1414Maximum fragment size: 183 ntPathogen Name: Cryptosporidium oocyst detectionGene: 18S rDNAForward Primer: CP1CCGAGTTTGA TCCAAAAAGT TACGAA                       SEQ ID No. 130!Reverse Primer: CP2TAGCTCCTCA TATGCCTTAT TGAGTA                       SEQ ID No. 131!Maximum fragment size: 452 ntPathogen Name: Cyclospora and Eimeria speciesGene: 18S rDNAForward Primer: CYC3FEGGAATTCCTT CCGAGCTTCG CTGCGT                       SEQ ID No. 132!Site of Specific Hybridization: nt 685-704Reverse Primer: CYC4RBCGGGATCCCG TCTTCAAACC CCCTACTG                       SEQ ID No. 133!Site of Specific Hybridization: nt 978-959Maximum fragment size: 294 ntIdentification of Bacterial Toxin GenesPathogen Name: Vibrio cholerae 01 containing cholera toxin gene(epidemic chloera)Gene: CTXAForward Primer: CTX2CGGGCAGATT CTAGACCTCC TG    SEQ ID No. 134!Site of Specific Hybridization: nt 73-94Reverse Primer: CTX3CGATGATCTT GGAGCATTCC CAC   SEQ ID No. 135!Site of Specific Hybridization: nt 614-636Maximum fragment size: 564 bpPathogen Name: Enterotoxigenic Escherichia coliGene: ST1a or ST1bForward Primer: ST1-1TTAATAGCAC CCGGTACAAG CAGG  SEQ ID No. 189!Site of Specific Hybridization: nt 243-266Reverse Primer: ST1-2CTTGACTCTT CAAAAGAGAA AATTAC                       SEQ ID No. 136!Site of Specific Hybridization: nt 127-144Maximum fragment size: 147 bpPathogen Name: Enterotoxigenic Escherichia coliGene: LT1a or LT1bForward Primer: LT1a/b-1TCTCTATRTG CAYACGGAGC       SEQ ID No. 137!Site of Specific Hybridization: nt 46-65Reverse Primer: LT1-2CCATACTGAT TGCCGCAAT        SEQ ID No. 138!Site of Specific Hybridization: nt 349-367Maximum fragment size: 322 bpPathogen Name: Enterotoxigenic Escherichia coliGene: SLTIIForward Primer: SLTII-1CTTCGGTATC CTATTCCCGG       SEQ ID No. 139!Site of Specific Hybridization: nt 288-307Reverse Primer: SLTII-2GGATGCATCT CTGGTCATTG       SEQ ID No. 140!Site of Specific Hybridization: nt 747-766Maximum fragment size: 478 bpPathogen Name: Shigella species and enteroinvasive E. coli(diarrheal disease)Gene: Invasion plasmid ial locusForward Primer: Sh-1CTGGATGGTA TGGTGAGG         SEQ ID No. 141!Reverse Primer: Sh-2GGAGGCCAAC AATTATTTCC       SEQ ID No. 142!Maximum fragment size: 320 bpPathogen Name: Helicobacter pylori (formerly Campylobacterpylori)Gene: genomicForward Primer: CAM-2TAACAAACCG ATAATGGCGC       SEQ ID No. 143!Reverse Primer: CAM-4CATCTTGTTA GAGGGATTGG       SEQ ID No. 144!Maximum fragment size: 203 bpPathogen Name: Toxigenic Clostridium difficileGene: rDNAForward Primer: PG-48CTCTTGAAAC TGGGAGACTT GA    SEQ ID No. 145!Reverse Primer: BCCGTCAATTC MTTTRAGTTT       SEQ ID No. 146!Maximum fragment size: 291 bpPathogen Name: Toxigenic Clostridium difficileGene: Toxin BForward Primer: YT-17GGTGGAGCTT CAATTGGAGA G     SEQ ID No. 147!Reverse Primer: YT-18GTGTAACCTA CTTTCATAAC ACCAG                       SEQ ID No. 148!Maximum fragment size: 399 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: seaForward Primer: SEA1TTGGAAACGG TTAAAACGAA       SEQ ID No. 149!Site of Specific Hybridization: nt 490-509Reverse Primer: SEA2GAACCTTCCC ATCAAAAACA       SEQ ID No. 150!Site of Specific Hybridization: nt 610-591Maximum fragment size: 120 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: sebForward Primer: SEB1TCGCATCAAA CTGACAAACG       SEQ ID No. 151!Site of Specific Hybridization: nt 634-653Reverse Primer: SEB2GCAGGTACTC TATAAGTGCC       SEQ ID No. 152!Site of Specific Hybridization: nt 1110-1091Maximum fragment size: 478 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: secForward Primer: SEC1GACATAAAAG CTAGGAATTT       SEQ ID No. 153!Site of Specific Hybridization: nt 676-695Reverse Primer: SEC2AAATCGGATT AACATTATCC       SEQ ID No. 154!Site of Specific Hybridization: nt 932-913Maximum fragment size: 257 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: sedForward Primer: SED1CTAGTTTGGT AATATCTCCT       SEQ ID No. 155!Site of Specific Hybridization: nt 354-373Reverse Primer: SED2TAATGCTATA TCTTATAGGG       SEQ ID No. 156!Site of Specific Hybridization: nt 671-652Maximum fragment size: 317 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: seeForward Primer: SEE1TAGATAAAGT TAAAACAAGC       SEQ ID No. 157!Site of Specific Hybridization: nt 491-510Reverse Primer: SEE2TAACTTACCG TGGACCCTTC       SEQ ID No. 158!Site of Specific Hybridization: nt 659-640Maximum fragment size: 170 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: tssForward Primer: TSST1ATGGCAGCAT CAGCTTGATA       SEQ ID No. 159!Site of Specific Hybridization: nt 251-270Reverse Primer: TSST2TTTCCAATAA CCACCCGTTT       SEQ ID No. 160!Site of Specific Hybridization: nt 600-581Maximum fragment size: 350 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: etaForward Primer: ETA1CTAGTGCATT TGTTATTCAA       SEQ ID No. 161!Site of Specific Hybridization: nt 374-393Reverse Primer: ETA2TGCATTGACA CCATAGTACT       SEQ ID No. 162!Site of Specific Hybridization: nt 492-473Maximum fragment size: 119 bpPathogen Name: Staphylococcus aureus toxins and virulence factorsGene: etbForward Primer: ETB1ACGGCTATAT ACATTCAATT       SEQ ID No. 163!Site of Specific Hybridization: nt 51-70Reverse Primer: ETB2TCCATCGATA ATATACCTAA       SEQ ID No. 164!Site of Specific Hybridization: nt 250-231Maximum fragment size: 200 bpPathogen Name: Bacterial meningitis (Haemophilus influenzae,Neisseria meningitidis, Streptococcus pneumonia, S. agalactiae,Listeria monocytogenes, enteric bacteria, or Mycobacteriumtuberculosis)Gene: 16s rDNAForward Primer: RW01AACTGGAGGA AGGTGGGGAT       SEQ ID No. 165!Reverse Primer: DG74AGGAGGTGAT CCAACCGCA        SEQ ID No. 166!Maximum fragment size: 370 ntPathogen Name: Streptococcus pyogenes exotoxins (StreptococcalToxic Shock Syndrome)Gene: speCForward Primer: FCCACCTTGAC TATTT            SEQ ID No. 167!Reverse Primer: RTTAATTAGGA GGTAA            SEQ ID No. 168!Maximum fragment size: 936 ntIdentification of Anti-Microbial Resistance LociPathogen Name: Rifampin Resistance Mutations in Mycobacteriumtuberculosis and M. lepraeGene: rpoBForward Primer: rpoB105CGTGGAGGCG ATCACACCGC AGACGT                       SEQ ID No. 169!Reverse Primer: rpoB293AGTGCGACGG GTGCACGTCG CGGACCT                       SEQ ID No. 170!Maximum fragment size: 215 ntPathogen Name: Human Immunodeficiency Virus Drug ResistanceGene: HIV Reverse TranscriptaseForward Primer: A(35)TTGGTTGCAC TTTAAATTTT CCCATTAGTC CTATT                       SEQ ID No. 171!Reverse Primer: NE-1(35)CCTACTAACT TCTGTATGTC ATTGACAGTC CAGCT                       SEQ ID No. 172!Maximum fragment size: 805 ntPathogen Name: erm Erythormycin Resistance Genes (in S. aureus,E. coli, or Bacillus sphaericus)Gene: ermForward Primer: E1GARATIGGII IIGGIAARGG ICA*  SEQ ID No. 173!Reverse Primer: E2AAYTGRTTYT TIGTRAA*         SEQ ID No. 174!Maximum fragment size: 530 nt*I = inosinePathogen Name: Methicillin-Resistant StaphylococcusGene: mecAForward Primer: RSM 2647AAAATCGATG GTAAAGGTTG GC    SEQ ID No. 175!Site of Specific Hybridization: nt 1282-1303Reverse Primer: RSM 2648AGTTCTGCAG TACCGGATTT GC    SEQ ID No. 176!Site of Specific Hybridization: nt 1814-1793Maximum fragment size: 533 ntPathogen Name: Penicillinase-Producing Neisseria gonorrhoeaeGene: TEM-1Forward Primer: PPNG-LAGTTATCTAC ACGACGG          SEQ ID No. 177!Reverse Primer: PPNG-RGGCGTACTAT TCACTCT          SEQ ID No. 178!Maximum fragment size: 761 ntPathogen Name: Aminoglycoside-Modifying EnzymesGene: aacC1Forward Primer: aacC1-1ACCTACTCCC AACATCAGCC       SEQ ID No. 179!Reverse Primer: aacC1-2ATATAGATCT CACTACGCGC       SEQ ID No. 180!Maximum fragment size: 169 ntPathogen Name: Extended Spectrum of Beta-lactamasesGene: TEM-1Forward Primer: Lag. Std. 3AGAGAATTAT GCAGTGC          SEQ ID No. 181!Site of Specific Hybridization: nt 560Reverse Primer: Amp. Primer 2GACAGTTACC AATGCTTAAT CA    SEQ ID No. 182!Site of Specific Hybridization: nt 1074Maximum fragment size: 514 ntPathogen Name: Fluoroquinolone Resistance mutations inMycobacterium tuberculosisGene: gyrAForward Primer: GyrA1CAGCTACATC GACTATGCGA       SEQ ID No. 183!Site of Specific Hybridization: nt 78-97Reverse Primer: GyrA2GGGCTTCGGT GTACCTCAT        SEQ ID No. 184!Site of Specific Hybridization: nt 379-397Maximum fragment size: 320 ntPathogen Name: Isoniazid Resitance of Mycobacterium tuberculosisGene: katGForward Primer: katG904AGCTCGTATG GCACCGGAAC       SEQ ID No. 185!Site of Specific Hybridization: nt 904Reverse Primer: katG1523TTGACCTCCC ACCCGACTTG       SEQ ID No. 186!Site of Specific Hybridization: nt 1523Maximum fragment size: 620 ntPathogen Name: Vancomycin resistant EnterococciGene: vanBForward Primer: VanB1CATCGCCGTC CCCGAATTTC AAA   SEQ ID No. 187!Reverse Primer: VanB2GATGCGGAAG ATACCGTGGC T     SEQ ID No. 188!Maximum fragment size: 297 nt__________________________________________________________________________

                                  APPENDIX II__________________________________________________________________________    10      20     30    40    50__________________________________________________________________________OMP-A-1  1A----A---A--AA---A--- A--A-----AAAAA--A--  50OMP-A-3  1A----A---A--AA-A-A--- A--A-----AAAAA--A--  50OMP-B-1  1 AA--------            AA----A-AAA--A-A--AA------AA---A  50OMP-B-2  1 AA--------            AA----A-AAA--A-A--AA------AA---A  50OMP-Ba-1  1 AA--------            AA----A-AAA--A-A--AA------AA---A  50OMP-C  1A----A---A--AA---A--- A--A-----AAAAA--A--  50OMP-D-1  1A-------- AA----A-AAA-A-A--AA-A----AA---A  50OMP-D-2  1A-------- AA----A-AAA-A-A--AA-A----AA---A  50OMP-Da  1A-------- AA----A-AAA-A-A--AA-A----AA---A  50OMP-E  1 AA------A-            AA----A-AAA--A-A--AA----A-AAA--A  50OMP-H  1A----A---A--AAA--A--- A--A-A---AAAAA--A--  50OMP-I  1A----A---A--AAA--A-A- A--A-----AAAAA--A--  50OMP-J  1A----A---A---A---A--- A--A-----AAAAA--A--  50OMP-K  1A----A---A--AA---A--- A-AA-----AAAAA--A--  50OMP-L1  1 AA--------            AA----A-A-A--A-A--AA------AA---A  50OMP-L2-1  1 AA--------            AA----A-AAA-A--AA------AA---A  50OMP-L2-3  1 AA--------            AA----A-AAA-A--AA-------A---A  50OMP-L3  1 AA--------A----A--AA---A-A- A--------AAAA--A--  50OMP-LGV  1 AA--------            AA----A-A-A-A--AA------AA---A  50__________________________________________________________________________    60      70     80    90    100__________________________________________________________________________OMP-A-1  51A--A--AAAAAA-----A----AA A-A-A---AA    100OMP-A-3  51A--A--AAAAAA-----A----AA A-A-A---AA    100OMP-B-1  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-B-2  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-Ba-1  51A-A-- AA-A-A-AA-A--A-A-A-A------- 100OMP-C  51AA-AA-AAAAAA-----A----AA A-A-A---AA    100OMP-D-1  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-D-2  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-Da  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-E  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-H  51AAAAA-AAAAAA-----A----AA A-A-A---AA    100OMP-I  51AA-AA-AAAAAA-----A----AA A-A-A---AA    100OMP-J  51AA-AA-AAAA--------AAA-----A----AA A-A-A---AA    100OMP-K  51AA-AA-AAAAAA-----A----AA A-A-A---AA    100OMP-L1  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-L2-1  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-L2-3  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100OMP-L3  51AA-AA-AAAAAA-----A----AA A-A-A---AA    100OMP-LGV  51A-A-- AA-A-A-AA-A--A-A-A-A--A---- 100__________________________________________________________________________    110     120    130   140   150__________________________________________________________________________OMP-A-1 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-A-3 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-B-1 101A-A-----AAAA------A----AAA-A---A------ 150OMP-B-2 101A-A-----AAAA------A----AAA-A---A------ 150OMP-Ba-1 101A-A-----AAAA------A----AAA-A---A------ 150OMP-C 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-D-1 101A-A-----AAAA------A----AAA-A---A------ 150OMP-D-2 101A-A-----AAAA------A----AAA-A---A------ 150OMP-Da 101A-A-----AAAA------A----AAA-A---A------ 150OMP-E 101A-A-----AAAA------A----AAA-A---A------ 150OMP-H 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-I 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-J 101A-----AAAA--AAA-    A----A--AA    A-A------A            150OMP-K 101A-----AAAA--AAA-    A----A--AA    A-A------A            150__________________________________________________________________________

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 189(2) INFORMATION FOR SEQ ID NO: 1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(xi) FEATURE:(D) OTHER INFORMATION: primer for sequencing of crypticplasmis(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:TCCGGAGCGAGTTACGAAGA20(2) INFORMATION FOR SEQ ID NO: 2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of crypticplasmid(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:ATTCAATGCCCGGGATTGGT20(2) INFORMATION FOR SEQ ID NO: 3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:CCGACCGCGTCTTGAAAACAGATGT25(2) INFORMATION FOR SEQ ID NO: 4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:CACCCACATTCCCAGAGAGCT21(2) INFORMATION FOR SEQ ID NO: 5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:CGTGCAGCTTTGTGGGAATGT21(2) INFORMATION FOR SEQ ID NO: 6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:CTAGATTTCATCTTGTTCAATTGC24(2) INFORMATION FOR SEQ ID NO: 7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:AGCATGCGTRTKGGTTACTAYGG23(2) INFORMATION FOR SEQ ID NO: 8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:TGACTTTGTTTTCGACCGYGTTTT24(2) INFORMATION FOR SEQ ID NO: 9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:CTAAAGTYGCRCATCCACATTCC23(2) INFORMATION FOR SEQ ID NO: 10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:CATCCACATTCCCASARAGCTGC23(2) INFORMATION FOR SEQ ID NO: 11:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of crypticplasmid(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:ATGCCCGGGATTGGTTGATC20(2) INFORMATION FOR SEQ ID NO: 12:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:GGAGACTTTGTTTTCGACCG20(2) INFORMATION FOR SEQ ID NO: 13:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:CATTCCCACAAAGCTGCGCG20(2) INFORMATION FOR SEQ ID NO: 14:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:TTCCCACAAAGCTGCGCGAG20(2) INFORMATION FOR SEQ ID NO: 15:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of VS regions(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:CCCACAAAGCTGCGCGAGCG20(2) INFORMATION FOR SEQ ID NO: 16:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of ribosomal DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:ACCTTTCGGTTGAGGGAGAGTCTA24(2) INFORMATION FOR SEQ ID NO: 17:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Chlamydia trachomatis(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of ribosomal DNA(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:GGACCAATTCTTATTCCCAAGCGA24(2) INFORMATION FOR SEQ ID NO: 18:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: HIV-1(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of HIV-1 proteasegene(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:ATCACTCTTTGGCAACGACC20(2) INFORMATION FOR SEQ ID NO: 19:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: HIV-1(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of HIV-1 proteasegene(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:CAGGAGCAGATGATACAGTATTAG24(2) INFORMATION FOR SEQ ID NO: 20:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: HIV-1(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of HIV-1 proteasegene(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:CCATTCCTGGCTTTAATTTTACTGG25(2) INFORMATION FOR SEQ ID NO: 21:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Human Papillomavirus(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of HPV(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:GCMCAGGGWCATAAYAATGG20(2) INFORMATION FOR SEQ ID NO: 22:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL:no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE:(A) ORGANISM: Human Papillomavirus(ix) FEATURE:(D) OTHER INFORMATION: primer for sequencing of HPV(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:CGTCCMAARGGAWACTGATC20(2) INFORMATION FOR SEQ ID NO: 23:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:TCAAAKGAATTGACGGGGGC20(2) INFORMATION FOR SEQ ID NO: 24:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:AGGCCCGGGAACGTATTCAC20(2) INFORMATION FOR SEQ ID NO: 25:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:TGCCAGCAGCCGCGGTAA18(2) INFORMATION FOR SEQ ID NO: 26:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:GGACTACCAGGGTATCTAAT20(2) INFORMATION FOR SEQ ID NO: 27:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:GAGGAAGGTGGGGATGACGT20(2) INFORMATION FOR SEQ ID NO: 28:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:AGGCCCGGGAACGTATTCAC20(2) INFORMATION FOR SEQ ID NO: 29:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:GAGAGTTTGATCCTGGCTCAG21(2) INFORMATION FOR SEQ ID NO: 30:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:CCCACTGCTGCCTCCCGTAG20(2) INFORMATION FOR SEQ ID NO: 31:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:GAGAGTTTGATCCTGGCTCAG21(2) INFORMATION FOR SEQ ID NO: 32:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:TTTCACGAACAACGCGACAA20(2) INFORMATION FOR SEQ ID NO: 33:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:CTCGTCCAGCGCCGCTTCGG20(2) INFORMATION FOR SEQ ID NO: 34:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:CCTGCGAGCGTAGGCGTCGG20(2) INFORMATION FOR SEQ ID NO: 35:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:TTCTCAATTCGGTAAGGC18(2) INFORMATION FOR SEQ ID NO: 36:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:ATATTGACCAGTGCTATTTC20(2) INFORMATION FOR SEQ ID NO: 37:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:CAATTGCTTATAACCTTTTGGTTATAAAT29(2) INFORMATION FOR SEQ ID NO: 38:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:TATAGGTACCGTCATTATCTTCCCTAT27(2) INFORMATION FOR SEQ ID NO: 39:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:TTATGAAAAAATATTTATTGGGAAT25(2) INFORMATION FOR SEQ ID NO: 40:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:CTTTAAGCTCAAGCTTGTCTACTGT25(2) INFORMATION FOR SEQ ID NO: 41:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:CTGCAGCTTGGAATTCAGGCACTTC25(2) INFORMATION FOR SEQ ID NO: 42:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:GTTTTGTAATTTCAACTGCTGACC24(2) INFORMATION FOR SEQ ID NO: 43:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:ATCTGTTACCAGCATGTAAT20(2) INFORMATION FOR SEQ ID NO: 44:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:CCCTCACTAAACATACCT18(2) INFORMATION FOR SEQ ID NO: 45:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:GATGATGCTGCTGGCATGGGAGTTTCTGG29(2) INFORMATION FOR SEQ ID NO: 46:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 31(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:CTGTCTGCATCTGAATATGTGCCGTTACCTG31(2) INFORMATION FOR SEQ ID NO: 47:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:ATCTTACTTTCCGTGAGAAG20(2) INFORMATION FOR SEQ ID NO: 48:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:CTTGGATGTTGAGCTTCCTA20(2) INFORMATION FOR SEQ ID NO: 49:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:TTGTGGTAGACACGGTGGGTAC22(2) INFORMATION FOR SEQ ID NO: 50:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:TGATCGCTGACAAGCTTAGGCT22(2) INFORMATION FOR SEQ ID NO: 51:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:CTCAGAGATGAGCCTGCGACCATT24(2) INFORMATION FOR SEQ ID NO: 52:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:GCATTCCCTCCCGTCCTCATTCTTC25(2) INFORMATION FOR SEQ ID NO: 53:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:GATAGCGAGCACAAAGAGAGCTAA24(2) INFORMATION FOR SEQ ID NO: 54:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 36(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:TTCACATCTGTTTGCAAAACACGGTCGAAAACAAAG36(2) INFORMATION FOR SEQ ID NO: 55:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:GTTGTTCATGAAGGCCTACT20(2) INFORMATION FOR SEQ ID NO: 56:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:TGCATAACCTACGGTGTGTT20(2) INFORMATION FOR SEQ ID NO: 57:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:GAAGCTTATGGTACAGGTTGG21(2) INFORMATION FOR SEQ ID NO: 58:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:ATTACCATCCTTGTTGTAAG20(2) INFORMATION FOR SEQ ID NO: 59:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:GGCGAATGGGTGAGTAACACG21(2) INFORMATION FOR SEQ ID NO: 60:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:CGGATAACGCTTGCGACCTATG22(2) INFORMATION FOR SEQ ID NO: 61:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:GCTATGAGGAATCTCGCTG19(2) INFORMATION FOR SEQ ID NO: 62:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:CTGGCTTCTTCCAGCTTCA19(2) INFORMATION FOR SEQ ID NO: 63:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:ATACACGTGGTGGAGGTAC19(2) INFORMATION FOR SEQ ID NO: 64:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:GCGGGCAATATCTTGCATC19(2) INFORMATION FOR SEQ ID NO: 65:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:GGTTATTCGATTTCTAAATCGCCT24(2) INFORMATION FOR SEQ ID NO: 66:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:GGACTATTGTCTAAACAATTTCCC24(2) INFORMATION FOR SEQ ID NO: 67:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:AGTTTGATCATGGCTCAG18(2) INFORMATION FOR SEQ ID NO: 68:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:GAGTTTGCCGGGACTTCTTCT21(2) INFORMATION FOR SEQ ID NO: 69:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:AGTTGGAGGACATCAAGCAGCCATGCAAAT30(2) INFORMATION FOR SEQ ID NO: 70:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:TGCTATGTCAGTTCCCCTTGGTTCTCT27(2) INFORMATION FOR SEQ ID NO: 71:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:CCCGGGCCCCCTGACTTGTC20(2) INFORMATION FOR SEQ ID NO: 72:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:GCTTTCACTGTCCCACAGCAG21(2) INFORMATION FOR SEQ ID NO: 73:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:CAAGGTATGTTGCCCGTTTG20(2) INFORMATION FOR SEQ ID NO: 74:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:AAAGCCCTGCGAACCACTGA20(2) INFORMATION FOR SEQ ID NO: 75:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:CCCAACACTACTCGGCTAG19(2) INFORMATION FOR SEQ ID NO: 76:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:AACTACTGTCTTCACGCAGAAAGC24(2) INFORMATION FOR SEQ ID NO: 77:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:TACATCGGCGTCATCTGCGGGG22(2) INFORMATION FOR SEQ ID NO: 78:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:CAGTTCGGCGGTGAGGACAAAG22(2) INFORMATION FOR SEQ ID NO: 79:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:AAGCTTGCACAATGCCAAAAAACAG25(2) INFORMATION FOR SEQ ID NO: 80:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:CTCGAGTATGCCGAGACCCCTAATC25(2) INFORMATION FOR SEQ ID NO: 81:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:TATCCCAGCTGTTTTCATATAGTAAC26(2) INFORMATION FOR SEQ ID NO: 82:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:GCCTTGCGGTAGCACTAGATTTTTTG26(2) INFORMATION FOR SEQ ID NO: 83:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:AAGGATGCCTGGACACAAGA20(2) INFORMATION FOR SEQ ID NO: 84:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:TGGTGCTGCTGGTGGTGGCAAT22(2) INFORMATION FOR SEQ ID NO: 85:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:CCTAGTGTGGATGACCTACGGGCCA25(2) INFORMATION FOR SEQ ID NO: 86:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:CAGACACAGTGTCCTCCCGCTCCTC25(2) INFORMATION FOR SEQ ID NO: 87:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:ATGTCCGTACAACATCAACT20(2) INFORMATION FOR SEQ ID NO: 88:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:CGATTTTCCAAGAGAGACGC20(2) INFORMATION FOR SEQ ID NO: 89:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:AGTCTTTAGGGTCTTCTACC20(2) INFORMATION FOR SEQ ID NO: 90:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:GGTGCCAACCTATGGAACAG20(2) INFORMATION FOR SEQ ID NO: 91:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:GGAACAGACTTAGAGCTTATTC22(2) INFORMATION FOR SEQ ID NO: 92:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:GCTTGTGTAAGTCTTCACTAG21(2) INFORMATION FOR SEQ ID NO: 93:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:CAATAGCTGGTTTTATAGAA20(2) INFORMATION FOR SEQ ID NO: 94:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:TTATCATACAGATTCTTGAC20(2) INFORMATION FOR SEQ ID NO: 95:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:GAAGGCAAAGCAGAACTAGC20(2) INFORMATION FOR SEQ ID NO: 96:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:TGGCCTTCTGCTATTTCAAA20(2) INFORMATION FOR SEQ ID NO: 97:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:GTGCAAACTGCATCTTGTGG20(2) INFORMATION FOR SEQ ID NO: 98:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:CTCATTTCTTGATCTCCATG20(2) INFORMATION FOR SEQ ID NO: 99:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:GGACCAAGAGAAAACGTAGC20(2) INFORMATION FOR SEQ ID NO: 100:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:GGTCACATCATACAATTCTAATCTAAG27(2) INFORMATION FOR SEQ ID NO: 101:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:ATGACTTTTGAGGTGGATCCCATGGA26(2) INFORMATION FOR SEQ ID NO: 102:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:GCCGAGAAGGGCGTGCGCAGGTA23(2) INFORMATION FOR SEQ ID NO: 103:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103:TGCTTTGCCCCATGGGACCTCGAG24(2) INFORMATION FOR SEQ ID NO: 104:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:GGCGAACACGCTCATCACGGT21(2) INFORMATION FOR SEQ ID NO: 105:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:CCTCCGGCCCCTGAATGCGGCTAAT25(2) INFORMATION FOR SEQ ID NO: 106:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:ATTGTCACCATAAGCAGCCA20(2) INFORMATION FOR SEQ ID NO: 107:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:GCMCAGGGWCATAAYAATGG20(2) INFORMATION FOR SEQ ID NO: 108:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108:CGTCCMAARGGAWACTGATC20(2) INFORMATION FOR SEQ ID NO: 109:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:CACTGAATAAGAGGATACAAGAATGG26(2) INFORMATION FOR SEQ ID NO: 110:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:GGAGGAATATTACATGTGCCTTT23(2) INFORMATION FOR SEQ ID NO: 111:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:TCCGTAGGTGAACCTGCGA19(2) INFORMATION FOR SEQ ID NO: 112:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:TCCTCCGCTTATTGATATGC20(2) INFORMATION FOR SEQ ID NO: 113:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:AGTTACGGCCATACCTCAGA20(2) INFORMATION FOR SEQ ID NO: 114:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:AAAGCTACAGCACGTCGTAT20(2) INFORMATION FOR SEQ ID NO: 115:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:GCAAGTCTGGTGCCAGCAGCC21(2) INFORMATION FOR SEQ ID NO: 116:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:CCGTCAATTCCTTTATGTTTCAGCCTT27(2) INFORMATION FOR SEQ ID NO: 117:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:AAATAATGKACGGGTGAGATGCATGA26(2) INFORMATION FOR SEQ ID NO: 118:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:GGGTTCGATTGGGGTTGGTGT21(2) INFORMATION FOR SEQ ID NO: 119:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:GTGGGGGAGGGGCGTTCT18(2) INFORMATION FOR SEQ ID NO: 120:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:ATTTTACACCAACCCCCAGTT21(2) INFORMATION FOR SEQ ID NO: 121:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:GGATAACTACGGAAAAGCTGTAGC24(2) INFORMATION FOR SEQ ID NO: 122:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122:CGACTTCTCCTTCCTTTAAAAGATAGG27(2) INFORMATION FOR SEQ ID NO: 123:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 32(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(ix) FEATURE:(D) OTHER INFORMATION: Maximum fragment size: about 500 nt(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:GTTCAAGATTAATAATTGCAATAATCTATCCC32(2) INFORMATION FOR SEQ ID NO: 124:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:GGCCAATTCATTCAATGAATTGAG24(2) INFORMATION FOR SEQ ID NO: 125:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:CTCAGATCTAGAAACAATGCTTCTC25(2) INFORMATION FOR SEQ ID NO: 126:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:CTTAGTATAAGCTTTTATACAGC23(2) INFORMATION FOR SEQ ID NO: 127:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127:ATAGGTCAGAAACTTGAATGATACA25(2) INFORMATION FOR SEQ ID NO: 128:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:GCGCACCAGGAATGTCTTGT20(2) INFORMATION FOR SEQ ID NO: 129:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:TCACCTACGGATACCTTGTT20(2) INFORMATION FOR SEQ ID NO: 130:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:CCGAGTTTGATCCAAAAAGTTACGAA26(2) INFORMATION FOR SEQ ID NO: 131:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:TAGCTCCTCATATGCCTTATTGAGTA26(2) INFORMATION FOR SEQ ID NO: 132:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:GGAATTCCTTCCGAGCTTCGCTGCGT26(2) INFORMATION FOR SEQ ID NO: 133:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 28(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:CGGGATCCCGTCTTCAAACCCCCTACTG28(2) INFORMATION FOR SEQ ID NO: 134:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:CGGGCAGATTCTAGACCTCCTG22(2) INFORMATION FOR SEQ ID NO: 135:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:CGATGATCTTGGAGCATTCCCAC23(2) INFORMATION FOR SEQ ID NO: 136:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:CTTGACTCTTCAAAAGAGAAAATTAC26(2) INFORMATION FOR SEQ ID NO: 137:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:TCTCTATRTGCAYACGGAGC20(2) INFORMATION FOR SEQ ID NO: 138:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138:CCATACTGATTGCCGCAAT19(2) INFORMATION FOR SEQ ID NO: 139:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:CTTCGGTATCCTATTCCCGG20(2) INFORMATION FOR SEQ ID NO: 140:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:GGATGCATCTCTGGTCATTG20(2) INFORMATION FOR SEQ ID NO: 141:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 18(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:CTGGATGGTATGGTGAGG18(2) INFORMATION FOR SEQ ID NO: 142:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:GGAGGCCAACAATTATTTCC20(2) INFORMATION FOR SEQ ID NO: 143:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:TAACAAACCGATAATGGCGC20(2) INFORMATION FOR SEQ ID NO: 144:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:CATCTTGTTAGAGGGATTGG20(2) INFORMATION FOR SEQ ID NO: 145:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:CTCTTGAAACTGGGAGACTTGA22(2) INFORMATION FOR SEQ ID NO: 146:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:CCGTCAATTCMTTTRAGTTT20(2) INFORMATION FOR SEQ ID NO: 147:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:GGTGGAGCTTCAATTGGAGAG21(2) INFORMATION FOR SEQ ID NO: 148:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 25(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:GTGTAACCTACTTTCATAACACCAG25(2) INFORMATION FOR SEQ ID NO: 149:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149:TTGGAAACGGTTAAAACGAA20(2) INFORMATION FOR SEQ ID NO: 150:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:GAACCTTCCCATCAAAAACA20(2) INFORMATION FOR SEQ ID NO: 151:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:TCGCATCAAACTGACAAACG20(2) INFORMATION FOR SEQ ID NO: 152:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:GCAGGTACTCTATAAGTGCC20(2) INFORMATION FOR SEQ ID NO: 153:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:GACATAAAAGCTAGGAATTT20(2) INFORMATION FOR SEQ ID NO: 154:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:AAATCGGATTAACATTATCC20(2) INFORMATION FOR SEQ ID NO: 155:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:CTAGTTTGGTAATATCTCCT20(2) INFORMATION FOR SEQ ID NO: 156:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:TAATGCTATATCTTATAGGG20(2) INFORMATION FOR SEQ ID NO: 157:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:TAGATAAAGTTAAAACAAGC20(2) INFORMATION FOR SEQ ID NO: 158:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:TAACTTACCGTGGACCCTTC20(2) INFORMATION FOR SEQ ID NO: 159:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:ATGGCAGCATCAGCTTGATA20(2) INFORMATION FOR SEQ ID NO: 160:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:TTTCCAATAACCACCCGTTT20(2) INFORMATION FOR SEQ ID NO: 161:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:CTAGTGCATTTGTTATTCAA20(2) INFORMATION FOR SEQ ID NO: 162:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:TGCATTGACACCATAGTACT20(2) INFORMATION FOR SEQ ID NO: 163:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:ACGGCTATATACATTCAATT20(2) INFORMATION FOR SEQ ID NO: 164:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:TCCATCGATAATATACCTAA20(2) INFORMATION FOR SEQ ID NO: 165:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:AACTGGAGGAAGGTGGGGAT20(2) INFORMATION FOR SEQ ID NO: 166:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:AGGAGGTGATCCAACCGCA19(2) INFORMATION FOR SEQ ID NO: 167:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 15(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:CCACCTTGACTATTT15(2) INFORMATION FOR SEQ ID NO: 168:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 15(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:TTAATTAGGAGGTAA15(2) INFORMATION FOR SEQ ID NO: 169:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 26(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:CGTGGAGGCGATCACACCGCAGACGT26(2) INFORMATION FOR SEQ ID NO: 170:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 27(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:AGTGCGACGGGTGCACGTCGCGGACCT27(2) INFORMATION FOR SEQ ID NO: 171:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:TTGGTTGCACTTTAAATTTTCCCATTAGTCCTATT35(2) INFORMATION FOR SEQ ID NO: 172:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 35(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:CCTACTAACTTCTGTATGTCATTGACAGTCCAGCT35(2) INFORMATION FOR SEQ ID NO: 173:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:GARATNGGNNNNGGNAARGGNCA23(2) INFORMATION FOR SEQ ID NO: 174:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:AAYTGRTTYTTNGTRAA17(2) INFORMATION FOR SEQ ID NO: 175:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:AAAATCGATGGTAAAGGTTGGC22(2) INFORMATION FOR SEQ ID NO: 176:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:AGTTCTGCAGTACCGGATTTGC22(2) INFORMATION FOR SEQ ID NO: 177:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:AGTTATCTACACGACGG17(2) INFORMATION FOR SEQ ID NO: 178:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:GGCGTACTATTCACTCT17(2) INFORMATION FOR SEQ ID NO: 179:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:ACCTACTCCCAACATCAGCC20(2) INFORMATION FOR SEQ ID NO: 180:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:ATATAGATCTCACTACGCGC20(2) INFORMATION FOR SEQ ID NO: 181:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:AGAGAATTATGCAGTGC17(2) INFORMATION FOR SEQ ID NO: 182:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 22(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:GACAGTTACCAATGCTTAATCA22(2) INFORMATION FOR SEQ ID NO: 183:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:CAGCTACATCGACTATGCGA20(2) INFORMATION FOR SEQ ID NO: 184:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 19(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:GGGCTTCGGTGTACCTCAT19(2) INFORMATION FOR SEQ ID NO: 185:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:AGCTCGTATGGCACCGGAAC20(2) INFORMATION FOR SEQ ID NO: 186:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 20(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:TTGACCTCCCACCCGACTTG20(2) INFORMATION FOR SEQ ID NO: 187:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 23(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:CATCGCCGTCCCCGAATTTCAAA23(2) INFORMATION FOR SEQ ID NO: 188:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 21(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: no(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:GATGCGGAAGATACCGTGGCT21(2) INFORMATION FOR SEQ ID NO: 189:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 24(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: other nucleic acid(iii) HYPOTHETICAL: no(iv) ANTI-SENSE: yes(v) FRAGMENT TYPE: internal(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:TTAATAGCACCCGGTACAAGCAGG24__________________________________________________________________________
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4683194 *Mar 28, 1985Jul 28, 1987Cetus CorporationMethod for detection of polymorphic restriction sites and nucleic acid sequences
US4683195 *Feb 7, 1986Jul 28, 1987Cetus CorporationOne of the first Polymerase Chain Reaction (PCR) patents
US4683202 *Oct 25, 1985Nov 27, 1990Cetus CorpTitle not available
US4729947 *Mar 29, 1984Mar 8, 1988The Board Of Regents Of The University Of NebraskaDNA sequencing
US4795699 *Jan 14, 1987Jan 3, 1989President And Fellows Of Harvard CollegeT7 DNA polymerase
US4800159 *Dec 17, 1986Jan 24, 1989Cetus CorporationProcess for amplifying, detecting, and/or cloning nucleic acid sequences
US4811218 *Jun 2, 1986Mar 7, 1989Applied Biosystems, Inc.Real time scanning electrophoresis apparatus for DNA sequencing
US4889818 *Jun 17, 1987Dec 26, 1989Cetus CorporationDna polymerase; isolated from thermus aquaticus; use in polymerase chain reaction (pcr)
US4942124 *Aug 4, 1988Jul 17, 1990President And Fellows Of Harvard CollegeGenetic engineering, vectors and sequencing dna, hhybridizing
US4965188 *Jun 17, 1987Oct 23, 1990Cetus CorporationReacting nucleic acid with oligonucleotide primer in presence of catalytic enzyme dna polymerase; polymerase chain reaction patent
US5008182 *Aug 15, 1989Apr 16, 1991Cetus CorporationDetection of AIDS associated virus by polymerase chain reaction
US5075216 *Sep 23, 1988Dec 24, 1991Cetus CorporationMethods for dna sequencing with thermus aquaticus dna polymerase
US5079352 *May 15, 1990Jan 7, 1992Cetus CorporationPurified thermostable enzyme
US5122345 *Jul 3, 1990Jun 16, 1992President And Fellows Of Harvard CollegeDna sequencing apparatus
US5124247 *Dec 11, 1989Jun 23, 1992Europaisches Laboratorium Fur Molekularbiologie (Embl)Process for sequencing nucleic acids
US5171534 *Oct 15, 1990Dec 15, 1992California Institute Of TechnologyElectrophoretic analysis of DNA fragments tagged with fluorophore; absorption or fluorescent photometer
US5175082 *Mar 19, 1987Dec 29, 1992Imperial Chemical Industries PlcMethod of characterizing genomic dna
US5176995 *Aug 15, 1989Jan 5, 1993Hoffmann-La Roche Inc.Detection of viruses by amplification and hybridization
US5207880 *Aug 21, 1990May 4, 1993The Board Of Regents Of The University Of NebraskaFluorescent marking of DNA, scanning and modulation
US5283171 *Aug 29, 1989Feb 1, 1994Hoffmann-La Roche Inc.Compositions for and detection of human papillomavirus by specific oligonucleotide polymerase primers using the polymerase chain reaction
US5352600 *Nov 5, 1992Oct 4, 1994Hoffmann-La Roche Inc.Purified thermostable enzyme
US5427911 *Jul 28, 1993Jun 27, 1995Yale UniversityCoupled amplification and sequencing of DNA
US5453355 *Sep 3, 1993Sep 26, 1995Abbott LaboratoriesOligonucleotides and methods for the detection of Neisseria gonorrhoeae
US5527898 *Jun 7, 1995Jun 18, 1996Hoffmann-La Roche Inc.Detection of human papillomavirus by the polymerase chain reaction
US5830657 *Jul 19, 1996Nov 3, 1998Visible Genetics Inc.Method for single-tube sequencing of nucleic acid polymers
EP0265293A2 *Dec 24, 1987Apr 27, 1988President And Fellows Of Harvard CollegeT7 DNA polymerase
EP0386859A2 *Dec 24, 1987Sep 12, 1990The President And Fellows Of Harvard CollegeT7 DNA polymerase
EP0655506A1 *Nov 24, 1994May 31, 1995President And Fellows Of Harvard CollegeDNA polymerases having modified nucleotide binding site for DNA sequencing
WO1989007149A1 *Jan 17, 1989Aug 10, 1989Mayo FoundationGenomic amplification with direct sequencing
WO1992018650A1 *Apr 10, 1992Oct 29, 1992Baxter Diagnostics IncDetection of dna/rna by fluorescence polarization
WO1993002212A1 *Jul 23, 1992Feb 4, 1993Univ Partnerships Pty LtdSingle step amplification and sequencing of nucleic acids
WO1993008305A1 *Oct 16, 1992Apr 29, 1993Dynal AsMethod of sequencing double stranded dna
WO1994026894A1 *May 12, 1994Nov 24, 1994Us HealthVON HIPPEL-LINDAU (VHL) DISEASE GENE AND CORRESPONDING cDNA AND METHODS FOR DETECTING CARRIERS OF THE VHL DISEASE GENE
WO1995004140A1 *Jul 28, 1994Feb 9, 1995Henriette M A AdriaanseProcess for isolating nucleic acid from gram positive microorganisms
WO1995006756A2 *Aug 18, 1994Mar 9, 1995Abbott LabOLIGONUCLEOTIDES AND METHODS FOR THE DETECTION OF $i(CHLAMYDIA TRACHOMATIS)
WO1996001909A1 *Jul 7, 1995Jan 25, 1996Visible Genetics IncMETHOD, REAGENTS AND KIT FOR DIAGNOSIS AND TARGETED SCREENING FOR p53 MUTATIONS
Non-Patent Citations
Reference
1Arnot et al. "Digital codes from hypervariable tandemly repeated DNA sequences in the Plasmodium falciparum circumsporozoite gene can genetically barcode isolates" Molec. Biochem. Parasitol. 61: 15-24 (1993).
2 *Arnot et al. Digital codes from hypervariable tandemly repeated DNA sequences in the Plasmodium falciparum circumsporozoite gene can genetically barcode isolates Molec. Biochem. Parasitol. 61: 15 24 (1993).
3Beebe et al., "Incidence of Neisseria gonorrhoeae Isolates Negative by Syva DDirect Fluorescent-Antibody Test but Positve by Gen-Prove Accuprobe Test in a Sexually Transmitted Disease Clinic Population" J. Clim. Microbiol. 31: 2535-2537 (1993).
4 *Beebe et al., Incidence of Neisseria gonorrhoeae Isolates Negative by Syva DDirect Fluorescent Antibody Test but Positve by Gen Prove Accuprobe Test in a Sexually Transmitted Disease Clinic Population J. Clim. Microbiol. 31: 2535 2537 (1993).
5Bej et al., "Detection of Coliform Bacteria and Escherichia coli by Multiplex Chain Reaction: Comparison with Defined Substrate and Plating Methods for Water Quality Monitoring" Appl. Environ. Microbiol. 57: 2429-2432 (1991).
6Bej et al., "Multiplex PCR amplification and immobilized cap utre probes for detection of bacterial pathogens and indicators in water" Molec. Cellular Probes 4: 353-365 (1990).
7 *Bej et al., Detection of Coliform Bacteria and Escherichia coli by Multiplex Chain Reaction: Comparison with Defined Substrate and Plating Methods for Water Quality Monitoring Appl. Environ. Microbiol. 57: 2429 2432 (1991).
8 *Bej et al., Multiplex PCR amplification and immobilized cap utre probes for detection of bacterial pathogens and indicators in water Molec. Cellular Probes 4: 353 365 (1990).
9Carothers et al., "Point Mutation Analysis in A Mammalian Gene: Rapid Preparation of Total RNA, PCR Amplification of cDNA, and Tag Sequencing by a Novel Method" BioTechniques 7: 494-498 (1989).
10 *Carothers et al., Point Mutation Analysis in A Mammalian Gene: Rapid Preparation of Total RNA, PCR Amplification of cDNA, and Tag Sequencing by a Novel Method BioTechniques 7: 494 498 (1989).
11Church et al., "Genomic Sequencing", Proc. Nat'l Acad. Sci. (USA) 81: 1991-1995 (1984).
12Church et al., "The Genomic Sequencing Technique", Medical Genetics: Past, Present, Future pp. 17-21 (1985).
13 *Church et al., Genomic Sequencing , Proc. Nat l Acad. Sci. ( USA ) 81: 1991 1995 (1984).
14 *Church et al., The Genomic Sequencing Technique , Medical Genetics: Past, Present, Future pp. 17 21 (1985).
15De Schryver et al., "Epidemiology of sexually transmitted diseases: the global picture", Bull. WHO 68: 639-654 (1990).
16 *De Schryver et al., Epidemiology of sexually transmitted diseases: the global picture , Bull. WHO 68: 639 654 (1990).
17Deng et al., "Simultaneous amplification and sequencing of genomic DNA (SAS): sequencing of 16S rRNA genes using total genomic DNA from Butyrovibrio fibrisolvens, and detection and genotyping of non-cultruable mycoplasma-like organisms directly from total DNA isolated from infected plants", J. Microbiol. Methods 17: 103-113 (1993).
18 *Deng et al., Simultaneous amplification and sequencing of genomic DNA (SAS): sequencing of 16S rRNA genes using total genomic DNA from Butyrovibrio fibrisolvens, and detection and genotyping of non cultruable mycoplasma like organisms directly from total DNA isolated from infected plants , J. Microbiol. Methods 17: 103 113 (1993).
19Eisenstein, B., "The Polymerase Chain Reaction", New Engl. J., Med. 332: 178-183 (1990).
20 *Eisenstein, B., The Polymerase Chain Reaction , New Engl. J., Med. 332: 178 183 (1990).
21Ellison et al., "Detection of Mutations and Polymorphisms Using Fluorescence-Based Dideoxy Fingerprinting (F-ddF)", Biotechniques 17: 742-753 (1994).
22 *Ellison et al., Detection of Mutations and Polymorphisms Using Fluorescence Based Dideoxy Fingerprinting (F ddF) , Biotechniques 17: 742 753 (1994).
23Erickson, D., "Diagnosis by DNA", Scientific American, p. 116 (1992).
24 *Erickson, D., Diagnosis by DNA , Scientific American, p. 116 (1992).
25Ewanowitch et al., "Major Outbreak of Pertussis in Northern Alberta Canada: Analysis of Discrepant Direct Fluorescent-Antibody Culture Results by Using Polymerase Chain Reaction Methodology" J. Clin. Microbiol. 31: 1715-1725 (1993).
26 *Ewanowitch et al., Major Outbreak of Pertussis in Northern Alberta Canada: Analysis of Discrepant Direct Fluorescent Antibody Culture Results by Using Polymerase Chain Reaction Methodology J. Clin. Microbiol. 31: 1715 1725 (1993).
27Gyllenstein et al., "Generation of single-stranded DNA by polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus", Proc. Nat'l Acad. Sci. USA 85: 7652-7656 (1988).
28 *Gyllenstein et al., Generation of single stranded DNA by polymerase chain reaction and its application to direct sequencing of the HLA DQA locus , Proc. Nat l Acad. Sci. USA 85: 7652 7656 (1988).
29Kaltenboeck et al, "Two-Step Polymerase Chain Reaction and Restriction Endonuclease Analyses Detect and Differentiate ompA DNA of Chlmaydia spp." J. Clin. Microbiol. 30: 1098-1104 (1992).
30 *Kaltenboeck et al, Two Step Polymerase Chain Reaction and Restriction Endonuclease Analyses Detect and Differentiate ompA DNA of Chlmaydia spp. J. Clin. Microbiol. 30: 1098 1104 (1992).
31Kretz et al., "Cycle Sequencing" in PCR Methods and Applications 3: S107-S112 (1994).
32 *Kretz et al., Cycle Sequencing in PCR Methods and Applications 3: S107 S112 (1994).
33Langemeier et al., "Application of Cycle Dideoxy Fingerprinting to Screening Heterogeneous Polpulations of the Equine Infectious Anemia Virus", Biotechniques 17 (1994).
34 *Langemeier et al., Application of Cycle Dideoxy Fingerprinting to Screening Heterogeneous Polpulations of the Equine Infectious Anemia Virus , Biotechniques 17 (1994).
35Mahony et al., "Confirmatory Polymerase Chain Reaction Testing for Chlamydia trachomatis in First-Void Urine from Asymptomatic and Symptomatic Men" J. Clin. Microbiol. 30: 2241-2245 (1992).
36Mahony et al., "Multiplex PCR for Detection of Chlamydia trachomatis and Neisseria gonorhoeae in Genitourinary specimens" J. Clin. Microbiol. 33: 3049-3053 (1995).
37 *Mahony et al., Confirmatory Polymerase Chain Reaction Testing for Chlamydia trachomatis in First Void Urine from Asymptomatic and Symptomatic Men J. Clin. Microbiol. 30: 2241 2245 (1992).
38 *Mahony et al., Multiplex PCR for Detection of Chlamydia trachomatis and Neisseria gonorhoeae in Genitourinary specimens J. Clin. Microbiol. 33: 3049 3053 (1995).
39Maxam et al., "A new method for sequencing DNA", Proc. Nat'l. Acad. Sci. (USA) 74: 560-564 (1977).
40 *Maxam et al., A new method for sequencing DNA , Proc. Nat l. Acad. Sci. ( USA ) 74: 560 564 (1977).
41Miller et al., "Chain Terminator Sequencing of Double-Stranded DNA With Built in Error Correction", General Atomics Pre-Print (1991).
42 *Miller et al., Chain Terminator Sequencing of Double Stranded DNA With Built in Error Correction , General Atomics Pre Print (1991).
43Mullis et al., "Specific Synthesis of DNA in Vitro via a Polymerase-Catalyzed Chain Reaction" Meth. Enzymol. 155: 335-350 (1987).
44 *Mullis et al., Specific Synthesis of DNA in Vitro via a Polymerase Catalyzed Chain Reaction Meth. Enzymol. 155: 335 350 (1987).
45 *Murakawa et al., :Direct Detection of HIV 1 RNA from AIDS and ARC Patient Samples DNA 7: 287 295 (1988).
46Murakawa et al., :Direct Detection of HIV-1 RNA from AIDS and ARC Patient Samples DNA 7: 287-295 (1988).
47Murray, V., "Improved Double-Stranded DNA Sequencing Using the Linear Polymerase Chain Reaction", Nucl. Acids Res. 17: 8889 (1989).
48 *Murray, V., Improved Double Stranded DNA Sequencing Using the Linear Polymerase Chain Reaction , Nucl. Acids Res. 17: 8889 (1989).
49Nuovo, G.J., "In situ PCR" in Dieffenbach et al., PCR Primer: A Laboratory Manual, pp. 235-248, Cold Spring Harbor Laboratory Press (1995).
50 *Nuovo, G.J., In situ PCR in Dieffenbach et al., PCR Primer: A Laboratory Manual, pp. 235 248, Cold Spring Harbor Laboratory Press (1995).
51Rao, V. B., "Direct-Sequencing of Polymerase Chain Reaction-Amplified DNA", Anal Biochem, 216: 1-14 (1994).
52 *Rao, V. B., Direct Sequencing of Polymerase Chain Reaction Amplified DNA , Anal Biochem, 216: 1 14 (1994).
53 *Reeve et al., A novel thermostable polymerase for DNA sequencing Nature 376: 796 797 (1995).
54Reeve et al., A novel thermostable polymerase for DNA sequencing Nature 376: 796-797 (1995).
55Roemer et al., "Simultaneous Bi-Directional Cycle Sequencing", Poster presented at 9th International Genome Sequencing and Analysis Conference, Hilton Head, SC, Sep. 1997.
56 *Roemer et al., Simultaneous Bi Directional Cycle Sequencing , Poster presented at 9 th International Genome Sequencing and Analysis Conference, Hilton Head, SC, Sep. 1997.
57Ruano et al., "Coupled Amplification and sequencing of geneomic DNA", Proc. Nat'l Acad. Sci (USA) 88: 2815-2819 (1991).
58Ruano et al., "Genotyping and haplotyping of polymorphisms directly from genomic DNA via coupled amplification and sequencing (CAS)" Nucl. Acids Res. 19: 6877-6882 (1991).
59 *Ruano et al., Automated Genomic Coupled Amplification and Sequencing (CAS) of the Mitochondrial D Loop, Genomic Analysis Conference, Hilton Head, Fall 1994.
60 *Ruano et al., Coupled Amplification and sequencing of geneomic DNA , Proc. Nat l Acad. Sci ( USA ) 88: 2815 2819 (1991).
61 *Ruano et al., Genotyping and haplotyping of polymorphisms directly from genomic DNA via coupled amplification and sequencing (CAS) Nucl. Acids Res. 19: 6877 6882 (1991).
62Sanger et al., "DNA sequencing with chain-terminating inhibitors" Proc. Nat'l. Acad. Sci. 74: 5463-5467 (1977).
63 *Sanger et al., DNA sequencing with chain terminating inhibitors Proc. Nat l. Acad. Sci. 74: 5463 5467 (1977).
64Sarkar et al., "Dideoxy Fingerprinting (ddF): A rapid and Efficient Screen for the Presence of Mutations" Genomics 13: 441-443 (1992).
65 *Sarkar et al., Dideoxy Fingerprinting (ddF): A rapid and Efficient Screen for the Presence of Mutations Genomics 13: 441 443 (1992).
66Smith et al., "Fluorescence Detection in automated DNA Sequence analysis" Nature 321: 674-679 (1986).
67 *Smith et al., Fluorescence Detection in automated DNA Sequence analysis Nature 321: 674 679 (1986).
68Tabor et al., "A single residue in DNA Polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy and dideoxynucleotides", Proc. Nat'l Acad. Sci. USA. 92: 6339-6343 (1995).
69 *Tabor et al., A single residue in DNA Polymerases of the Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy and dideoxynucleotides , Proc. Nat l Acad. Sci. USA. 92: 6339 6343 (1995).
70 *Thermosequenase Product Insert (1995).
71Warren et al., "Comparative Evaulation of Detection Assays for Chlamydia trachomatis" J. Clin. Microbiol. 31: 1663-1666 (1993).
72 *Warren et al., Comparative Evaulation of Detection Assays for Chlamydia trachomatis J. Clin. Microbiol. 31: 1663 1666 (1993).
73Way et al., "Specific Detection of Salmonella spp. by Multiplex Polymerase Chain Reaction" Appl. Environ. Microbiol. 59: 1473-1479 (1993).
74 *Way et al., Specific Detection of Salmonella spp. by Multiplex Polymerase Chain Reaction Appl. Environ. Microbiol. 59: 1473 1479 (1993).
75Wiemann et al., "Simultaneous On-Line Sequencing on Both Strands with Two Fluorescent Dyes" Anal. Biochem. 224: 117-121 (1995).
76 *Wiemann et al., Simultaneous On Line Sequencing on Both Strands with Two Fluorescent Dyes Anal. Biochem. 224: 117 121 (1995).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6214548 *Jan 29, 1998Apr 10, 2001The United States Of America As Represented By The Secretary Of The ArmyDiagnostic methods for Cyclospora
US6265152 *Oct 15, 1999Jul 24, 2001Visible Genetics Inc.Method and kit for evaluation of HIV mutations
US6605451Jun 6, 2000Aug 12, 2003Xtrana, Inc.Methods and devices for multiplexing amplification reactions
US6673568Oct 24, 2000Jan 6, 2004Genprime, Inc.Kits; cyanine dyes; bacteria/not specific/; use of fluorescent dye to rapidly quantify viable cells having importance in food, pharmaceutical, environmental, manufacturing and clinic industries
US6787302Mar 1, 2002Sep 7, 2004Genprime, Inc.Detecting viable cells in sample; obtain cells, incubate with fluorescent dyes, detect fluorescence, compare to control
US6830887Feb 25, 2002Dec 14, 2004Bayer Healthcare LlcQuantitative and qualitative analysis of lymphadenopathy associated viral nucleotide sequences; diagnosis viral diseases
US7087414May 19, 2003Aug 8, 2006Applera CorporationDiscriminately identifying nucleic acid sequences of coliform bacteria; high throughput assay
US7294709 *Mar 9, 2004Nov 13, 2007Macquarie Research Ltd.Using ribosomal RNA as diagnostic tool in detection of protozoal infection
US7309589 *Aug 16, 2005Dec 18, 2007Vironix LlcSensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
US7319012May 29, 2002Jan 15, 2008Gene Therapy Systems, Inc.Generating library of preferential polypeptides; obtain nucleotide sequences, incubate with primers, amplify, recover amplification product, transform and express sequence incell, monitor and evaluate cell activity
US7531328Jul 7, 2005May 12, 2009Applied Biosystem, LlcMethods and devices for multiplexing amplification reactions
US7655443 *May 5, 2000Feb 2, 2010Siemens Healthcare Diagnostics, Inc.Nucleic acid sequencing with simultaneous quantitation
US8304214Nov 21, 2007Nov 6, 2012Applied Biosystems, LlcMethods for multiplexing amplification reactions
US8323897Nov 26, 2003Dec 4, 2012Applied Biosystems, LlcMultiplex amplification of polynucleotides
US8354226Jul 25, 2006Jan 15, 2013Gen-Probe IncorporatedAssay for detection of human parvovirus B19 nucleic acid
US8541171Dec 12, 2012Sep 24, 2013Gen-Probe IncorporatedAssay for detection of human parvovirus B19 nucleic acid
US20090298049 *Dec 1, 2008Dec 3, 2009Handylab, Inc.Methods for sample tracking
US20100222289 *Oct 22, 2008Sep 2, 2010Cfs Research LlcMethods for diagnosis and treatment of chronic fatigue syndrome
EP1045034A2 *Mar 9, 2000Oct 18, 2000Becton Dickinson and CompanyAmplification and detection of shiga-like toxin II producing organisms
WO2002097051A2 *May 29, 2002Dec 5, 2002Gene Therapy Systems IncProtein arrays and methods and systems for producing the same
Classifications
U.S. Classification435/6.12, 435/91.2
International ClassificationB01L7/00, C12Q1/70, G01N35/00, C12Q1/68
Cooperative ClassificationC12Q1/6869, C12Q1/6858, B01L7/52, C12Q1/6841, B01L7/525, C12Q1/689, G01N2035/00237, C12Q1/6881, C12Q1/703
European ClassificationB01L7/52, B01L7/525, C12Q1/68E, C12Q1/70B2B, C12Q1/68M10B, C12Q1/68D2G, C12Q1/68M4, C12Q1/68B14
Legal Events
DateCodeEventDescription
Aug 11, 2010FPAYFee payment
Year of fee payment: 12
Mar 26, 2010ASAssignment
Effective date: 20100118
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC.,NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER HEALTHCARE LLC;REEL/FRAME:024140/0465
Oct 2, 2006FPAYFee payment
Year of fee payment: 8
Apr 7, 2004ASAssignment
Owner name: BAYER HEALTHCARE LLC, NEW YORK
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VISIBLE GENETICS, INC.;REEL/FRAME:014499/0677
Effective date: 20030401
Owner name: BAYER HEALTHCARE LLC 511 BENEDICT AVENUETARRYTOWN,
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VISIBLE GENETICS, INC. /AR;REEL/FRAME:014499/0677
Owner name: BAYER HEALTHCARE LLC,NEW YORK
Aug 15, 2002FPAYFee payment
Year of fee payment: 4
Aug 16, 1999ASAssignment
Owner name: VISIBLE GENETICS INC., CANADA
Free format text: RELEASE;ASSIGNORS:HILAL CAPITAL, LP;HILAL CAPITAL QP, LP;REEL/FRAME:010133/0016
Effective date: 19990715
May 22, 1998ASAssignment
Owner name: C.J. PARTNERS, NEW YORK
Free format text: SECURITY INTEREST;ASSIGNOR:VISIBLE GENETICS, INC.;REEL/FRAME:009199/0762
Effective date: 19980430
Owner name: HIGHBRIDGE INTERNATIONAL LLC, NEW YORK
Owner name: HILAL CAPITAL INTERNATIONAL, LTD., NEW YORK
Owner name: HILAL CAPITAL QP, LP, NEW YORK
Owner name: HILAL CAPITAL, LP, NEW YORK
May 21, 1997ASAssignment
Owner name: VISIBLE GENETICS INC., CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LACROIX, JEAN-MICHEL;LEUSHNER, JAMES;HUI, MAY;AND OTHERS;REEL/FRAME:008518/0737;SIGNING DATES FROM 19970423 TO 19970519